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Abstract
PAX3 is a transcription factor. It plays a major role in the development of melanocytes in the
embryo. As a result of alternative splicing, the gene gives rise to eight different transcripts
which encode proteins that have differing structures and are therefore likely to activate
different downstream target genes. The presence of post-translational modifications has
also been shown to alter the functions of the proteins.
PAX3 regulates the maintenance of undifferentiated melanoblasts and mediates pathways
involved in proliferation, migration and survival. It has been shown to be expressed in
melanoblasts, adult melanocytes, naevi and in most melanoma cells. This implies that PAX3
may be involved in such regulatory pathways in all of these cell types including melanoma.
Melanoma is a notoriously aggressive and drug resistant form of skin cancer. Research into
the role of PAX3 in melanoma could provide novel treatment options for targeted therapies
aimed at PAX3 or its regulatory pathways.
Therefore, in this study, the expression profile of PAX3 alternate transcripts was compared
in normal melanocytes and melanoma cells. Moreover, differences in post-translational
modifications between these cell types were assessed, as were changes in downstream
target genes. This research further clarifies the role of PAX3 in melanoma and details the
differences in its role here, relative to that in melanocytes.

iii

Declaration
I certify that this thesis does not, to the best of my knowledge and belief:
(i)

incorporate without acknowledgement any material previously submitted for a
degree or diploma in any institution of higher education;

(ii)

contain any material previously published or written by another person except
where due reference is made in the text of the thesis; or

(iii)

contain any defamatory material.

I also grant permission for the Library at Edith Cowan University to make duplicate copies of
my thesis as required.

MSc candidate: Danielle Bartlett
Date: 18th November 2013

iv

Acknowledgements
I would like to thank the following people for helping to make this research possible:
Dr Glen Boyle of the Queensland Institute of Medical Research, for providing us with much
appreciated primary melanoma cell lines;
Professor Wallace Langdon, University of Western Australia, for his technical advice with
immunoprecipitation methodology;
Linda Wijaya and Michael Morici, Research Assistants, and Imran Khan, PhD student, at the
Centre of Excellence for Alzheimer’s Disease Research and Care, for their technical advice
with western blot methodology;
Dr Eugene Hone, Postdoctoral Research Fellow, and Dr Renae Barr, Research Fellow, at the
Centre of Excellence for Alzheimer’s Disease Research and Care, for their technical advice
with immunoprecipitation methodology;
Alvaro Reyes, PhD student at Edith Cowan University, for his advice with statistical analysis
of data;
James Freeman, Research Assistant, and Leslie Calapre, PhD student, at the Melanoma
Research Foundation at Edith Cowan University, for their advice with cell culture and
immunocytochemistry techniques;
Dr Elin Gray, Postdoctoral Fellow, and Anna Reid, Research Assistant, at the Melanoma
Research Foundation at Edith Cowan University, for their continued guidance and technical
advice;
Kitiya Dufall, Laboratory Manager at Edith Cowan University, for ordering materials required
for this research, technical advice and providing opportunities for further developing
laboratory skills;
The Melanoma Research Foundation team at Edith Cowan University;
My much valued and respected supervisors, Dr Sandra Medic and Professor Melanie Ziman,
for their constant support and exceptional supervision, for providing opportunities to
v

further develop my personal and professional skills with suggestions of conferences and
collaborative research meetings and for always giving their time to listen and provide much
needed and appreciated advice and guidance;
and finally I would like to thank my family, for being there and supporting me throughout
this project and for their constant love and guidance.

vi

Contents
Abstract .................................................................................................................................................. iii
Declaration ............................................................................................................................................. iv
Acknowledgements................................................................................................................................. v
List of Figures ......................................................................................................................................... ix
List of Tables ........................................................................................................................................... x
List of Abbreviations .............................................................................................................................. xi
1.

Introduction .................................................................................................................................... 1

2.

Literature review............................................................................................................................. 1

2.1

The development of melanoma .................................................................................................. 2

2.2

Risk factors for melanoma .......................................................................................................... 4

2.3

Treatment of melanoma ............................................................................................................. 5

2.4

Introduction to PAX3................................................................................................................... 6

2.5

PAX3 in melanocyte development, melanoblast maintenance and melanogenesis ................ 10

2.6

PAX3 in cell cycle inhibition and maintenance of stem cells .................................................... 12

2.7

Downstream target genes of PAX3 ........................................................................................... 13

2.8

Downstream targets of PAX3 differentially regulated in melanocytes and melanoma cells ... 15

2.9

Post-translational modifications of PAX3 ................................................................................. 24

3.

Theoretical Framework ................................................................................................................. 27

4.

Hypotheses ................................................................................................................................... 28

5.

Aims............................................................................................................................................... 28

6.

Methods and Materials ................................................................................................................. 29

6.1

Summary ................................................................................................................................... 29

6.2

Cell cultures............................................................................................................................... 29

6.3

RNA extraction .......................................................................................................................... 30

6.4

Reverse transcription and qPCR................................................................................................ 31

6.5

RNAseq ...................................................................................................................................... 34

6.6

Immunocytochemistry .............................................................................................................. 35

6.7

Western blot ............................................................................................................................. 36

6.8

Post-translational modifications of PAX3 proteins (phosphorylation, acetylation, and
ubiquitination) .......................................................................................................................... 38

6.9

PAX3 silencing and analysis of PAX3 downstream targets in melanoma cell lines and primary
melanocytes .............................................................................................................................. 41

7.
7.1

Results ........................................................................................................................................... 42
Clarifying consistency of PAX3 expression within groups of cell lines...................................... 42
vii

7.1.1

PAX3 expression analysed by immunocytochemistry .......................................................... 42

7.1.2

PAX3 expression analysed by Reverse-Transcriptase Polymerase Chain Reaction (RT-qPCR) .
.............................................................................................................................................. 45

7.1.3

Western blot ......................................................................................................................... 48

7.2

RNAseq to assess differential expression of PAX3 transcripts.................................................. 52

7.3

Testing for post-translational modifications............................................................................. 54

7.3.1

Optimisation of immunoprecipitation procedure ................................................................ 54

7.3.2

Immunoprecipitation and western blot................................................................................ 58

7.4

PAX3 silencing and downstream targets .................................................................................. 60

7.4.1

Expression levels of PAX3 downstream targets involved in cell differentiation following PAX3
silencing ................................................................................................................................... 62

7.4.2

Expression levels of PAX3 downstream targets involved in cell proliferation following PAX3
silencing ................................................................................................................................... 64

7.4.3

Expression levels of PAX3 downstream targets involved in cell survival following PAX3
silencing ................................................................................................................................... 66

7.4.4

Expression levels of PAX3 downstream targets involved in cell migration following PAX3
silencing ................................................................................................................................... 68

8.

Discussion...................................................................................................................................... 70

8.1

PAX3E expression is downregulated in melanoma cells compared to melanocytes ................ 70

8.2

Differential PAX3 acetylation, phosphorylation and ubiquitination in metastatic melanoma
cells compared to primary melanoma cells and melanocytes.................................................. 71

8.3

Knockdown of PAX3 differentially downregulates key genes involved in cell differentiation,
proliferation, migration and survival in melanoma cells compared to melanocytes ............... 76

8.4

Limitations of the study and suggested future experiments .................................................... 78

9.

Conclusion ..................................................................................................................................... 80

10. References..................................................................................................................................... 82

viii

List of Figures

Figure 1: The epidermal melanocyte-keratinocyte unit ......................................................................... 4
Figure 2: The entire PAX3 gene and alternate transcripts ...................................................................... 9
Figure 3: The expression of Pax3 as early as stage E8.5 in mouse neural crest cells ........................... 11
Figure 4: Differential binding by PAX3 to downstream target genes ................................................... 14
Figure 5: RT-qPCR analysis of relative expression of downstream target genes of PAX3 .................... 14
Figure 6: PAX3 expression in naevi, primary melanoma and metastatic melanoma relative to that of
normal skin............................................................................................................................................ 15
Figure 7: The role of Pax3 in melanogenesis ........................................................................................ 16
Figure 8: The genes involved in melanogenesis ................................................................................... 18
Figure 9: The interaction between Pax3, Dct and Wnt ......................................................................... 19
Figure 10: The interaction between keratinocytes and melanocytes and keratinocytes and melanoma
cells ....................................................................................................................................................... 23
Figure 11: Acetylation of PAX3 ............................................................................................................. 26
Figure 12: The process of ubiquitination .............................................................................................. 26
Figure 13: Sites of action for the PAX3 forward and reverse primers .................................................. 33
Figure 14: Illumina HiSeq 2000 protocol............................................................................................... 35
Figure 15: Immunocytochemistry of neonatal and adult human epidermal melanocytes, five
metastatic melanoma cell lines and six primary melanoma cell lines .................................................. 44
Figure 16: RT-qPCR on six primary and five metastatic cell lines and neonatal and adult normal
human epidermal melanocytes ............................................................................................................ 45
Figure 17: Western blot results ............................................................................................................ 48
Figure 18: PAX3 protein expression relative to β-actin expression ...................................................... 49
Figure 19: A comparison of PAX3E expression levels between neonatal and adult melanocytes and
MM540 and M14 melanoma cell lines ................................................................................................. 53
Figure 20: Optimisation of the immunoprecipitation procedure ......................................................... 55
Figure 21: Optimisation of the direct immunoprecipitation procedure ............................................... 56
Figure 22: Optimisation of the immunoprecipitation procedure ......................................................... 57
Figure 23: Immunoprecipitation using anti-acetylysine, anti-phosphoserine and anti-ubiquitin ........ 58
Figure 24: Percentage of remaining mRNA expression of PAX3 following silencing with siPAX3 and
GAPDH following silencing with siGAPDH............................................................................................. 61
Figure 25: Remaining expression levels (%) of PAX3 downstream targets MITF, DCT, HES1, SOX9 and
NES ........................................................................................................................................................ 63
Figure 26: Expression levels (%) of PAX3 downstream targets CCNA2 and TPD52 .............................. 65
Figure 27: Expression levels (%) of PAX3 downstream targets BCL2L1, PTEN and TGFβ1 ................... 67
Figure 28: Expression levels (%) of PAX3 downstream targets MCAM, CSPG4 and CXCR4 .................. 69
Figure 29: Additional potential sites of acetylation on the PAX3 protein ............................................ 73

ix

List of Tables

Table 1: Primers used in RT-qPCR analysis ........................................................................................... 32
Table 2: The binding sites and catalogue numbers for the antibodies used in western blot and
immunoprecipitation procedures ......................................................................................................... 40
Table 3: mRNA levels of PAX3 in melanocytes, primary melanoma cells and metastatic melanoma
cells ....................................................................................................................................................... 47
Table 4: Protein levels of PAX3 in neonatal and adult melanocytes and primary and metastatic
melanoma cells ..................................................................................................................................... 51

x

List of Abbreviations
Akt:

also known as protein kinase B (PKB), serine/threonin protein kinase Akt

APC:

antigen presenting cell

BCL2L1:

BCL2-like protein 1 (also known as BCL-XL)

BRAF:

v-raf murine sarcoma viral oncogene homologue B1

CCNA2:

cyclin A2

CDK4:

cyclin-dependent kinase 4

CDKN2A:

cyclin-dependent kinase inhibitor 2A

cDNA:

complementary deoxyribonucleic acid

CREB:

cAMP (cyclic adenosine monophosphate) response element binding

CSPG4:

chondroitin sulphate proteoglycan 4 (also known as MCSP or HMW-MAA)

CXCR4:

CXC chemokine receptor 4

Dct:

dopachrome tautomerase (also known as Trp-2- tyrosinase related protein 2)

DNA:

deoxyribonucleic acid

DSHB:

Developmental Studies Hybridoma Bank

EDTA:

ethylenediaminetetraacetic acid

FBS:

foetal bovine serum

GAPDH:

glyceraldehydes-3-phosphate dehydrogenase

GSK3:

glycogen synthase kinase 3

HES1:

hairy and enhancer of split 1

Lef1:

lymphoid enhancer binding factor 1

MCAM:

melanoma cell adhesion molecule

MDM2:

murine double minute 2

MITF:

microphthalmia-associated transcription factor

mRNA:

messenger ribonucleic acid

NES:

nestin

Neurog2:

neurogenin 2

NFKβ2:

nuclear factor kappa beta 2

xi

NGS:

normal goat serum

NRAS:

neuroblastoma RAS viral oncogene homologue

PAX3:

paired box 3

PBS:

phosphate buffered saline

PCR:

polymerase chain reaction

PDGF:

platelet derived growth factor

PIP3:

phosphatidylinositol (3,4,5)-triphosphate

PTEN:

phosphatase and tensin homologue

qPCR:

quantitative polymerase chain reaction

RNA:

ribonucleic acid

RT-PCR:

reverse transcription polymerase chain reaction

RT-qPCR:

real time quantitative polymerase chain reaction

Shc:

squalene-hopene cyclase

siRNA:

small inhibitor ribonucleic acid

SIRT1:

sirtuin 1

SOX9:

SRY (sex-determining region Y) box 9

SOX10:

SRY (sex-determining region Y) box 10

TAE:

tris base, acetic acid and EDTA buffer

TCF:

T cell factor

TGF-β:

transforming growth factor beta

TPA:

tissue plasminogen activator

TPD52:

tumour protein 52

Trp-1:

tyrosinase related protein 1 (also known as Tyrp1)

TX-TBS:

Triton X-100 tris buffered saline

Tyr:

tyrosinase

Wnt:

wingless type MMTV integration site family

PAX3/Pax3

protein in humans and mice, respectively

PAX3/Pax3

gene in humans and mice, respectively
xii

1.

Introduction

Cutaneous Malignant Melanoma (from here on referred to as melanoma) is a skin cancer
that arises from normal skin melanocytes. Studies have shown that the expression of the
developmental gene, PAX3, is required for neural crest cells to commit to the melanocyte
lineage and for proliferation. PAX3 is expressed across all cells of the melanocytic lineage,
including the cells of naevi and melanoma. Furthermore, PAX3 has been shown to
differentially regulate downstream target genes in melanoma cells compared to
melanocytes. Thus further research into the role of PAX3 in melanocytes and melanoma
cells is required in order to assess whether PAX3 is involved in key cellular processes that
drive melanomagenesis and whether these pathways differ from those in melanocytes.

2.

Literature review

The most aggressive form of skin cancer is cutaneous melanoma (Chin et al., 2006).
Melanoma is responsible for only 4% of skin cancers, but accounts for 80% of deaths from
skin cancer (Lewis et al., 2005). Moreover, metastatic melanoma is highly resistant to most
drug therapies, making it difficult to treat (Chen et al., 2006; Chin et al., 2006). Melanoma is
the most common cancer in people aged 15-39 years and the third most common cancer in
people aged 40 years and above and is more frequent in males than in females (Threlfall and
Thompson, 2010). Over ten thousand new cases are diagnosed every year in Australia
(Cancer Council Australia, 2012).
Melanoma is categorised clinically into Tumour, Node, Metastasis (TNM) stages 0, I, II, III
and IV. During early stage melanoma (stages 0, I and II) the tumour is confined to the
epidermal and dermal layers of the skin. At this point, the lesion can be excised from the
skin. For patients with early stage melanoma, the 5-year survival rate is 95% (Balch et al.,
2009). As the disease progresses the tumour cells migrate through the underlying layers of
skin and can invade blood and lymph vessels, allowing the aberrant cells to travel
throughout the body and establish secondary tumours. For patients with advanced stage
metastatic melanoma the 5-year survival rate drops significantly to below 45% (Balch et al.,
1

2009). Currently, there are limited safe and effective treatment options available for
metastatic melanoma (reviewed in Mackiewicz-Wysocka et al., 2013). This highlights the
importance of further investigations into the mechanisms behind melanoma formation and
progression so that an effective treatment focussed on inhibiting the pathways involved in
disease progression can be developed.
The paired box 3 gene (PAX3 in humans, Pax3 in mice) plays a crucial role in specification,
proliferation and migration of melanocytes in the embryo (Bang et al., 1997; Goulding et al.,
1991; Hornyak et al., 2001). PAX3 continues to be expressed in normal melanocytes of the
adult epidermis and is also expressed in naevi and melanoma cells (He et al., 2010; Medic
and Ziman, 2010). Exposure to ultraviolet (UV) radiation is known to be linked to melanoma
development. Following UV exposure, PAX3 is seen to be up-regulated in normal
melanocytes, resulting in an increase in melanocyte proliferation (Dong et al., 2012; Yang et
al., 2008). Since PAX3 is commonly expressed in melanomas (Medic et al., 2011; Medic and
Ziman, 2010; Plummer et al., 2008; Scholl et al., 2001), this raises the possibility that PAX3 is
involved in pathways that cause the transformation of melanocytes to malignant melanoma
cells.

2.1

The development of melanoma

Normal skin contains neural crest derived melanocytes at the dermal-epidermal border and
keratinocytes, the most abundant cell type in the epidermis. The number of keratinocytes is
greater than that of melanocytes, usually in the ratio of one melanocyte for every 36
keratinocytes. The melanocytes in naevi (a benign melanocytic lesion), and in melanomas,
however, far outnumber the keratinocytes (Hauschild et al., 2011; Hsu et al., 2002).
Therefore, keratinocytes, which regulate the growth of melanocytes and maintain their
correct location in the skin, have diminished control of melanocytes in these lesions.
Melanocytes in naevi ultimately become quiescent and proliferation ceases (Li et al., 2003).
These melanocytes do, however, have the potential to progress to radial growth phase
melanoma tumours.
Melanoma can arise from naevi or occur spontaneously (de novo) (Weatherhead et al.,
2006). The transformed cells proliferate and spread in a radial manner within the epidermis,
2

known as the radial growth phase. Subsequently, if left to continue proliferating, the
melanoma cells enter the vertical growth phase, where melanoma cells invade the dermis
(Crowson et al., 2006). Melanoma cells have a propensity to metastasise, which involves
their migration through the dermis, entrance into blood and lymph vessels and
dissemination to distant sites where secondary tumours can arise (Hsu et al., 2002).
In response to UV radiation, melanin is produced in melanocytes, a process termed
melanogenesis. There are two types of melanin produced as a result of melanogenesis;
eumelanin and pheomelanin. Eumelanin is a brown/black pigment and pheomelanin, a
red/yellow pigment. Together, these pigments give the skin and hair their colour and
protect the DNA of epidermal cells from UV radiation (Hearing, 2011).
During the process of melanogenesis, melanin is packaged into melanosomes that travel
along the dendritic projections of the melanocytes to the keratinocytes. One melanocyte
may serve up to 36 keratinocytes and this is known as an epidermal-melanin unit (Figure 1).
The melanin forms a barrier around the keratinocyte nucleus, preventing UV radiation from
damaging the DNA of dividing keratinocytes (Hsu et al., 2002; Yamaguchi et al., 2007).
Exposure to excessive UV radiation is known to cause an increase in melanogenesis and
contributes to darkening of the skin, or tanning (Tadokoro et al., 2005).

3

Surrounding
keratinocytes

Melanocyte

Figure 1: The epidermal melanocyte-keratinocyte unit. Note the long dendritic projections
of the melanocyte that transport the melanin to surrounding keratinocytes. Adapted from
Junqueira et al (1998).

2.2

Risk factors for melanoma

The risk factors associated with melanoma development can be divided into two categories;
those that are environmental and those that are genetic (Cho and Chiang, 2010; Goodall et
al., 2008). The main environmental risk factor associated with melanoma development is UV
radiation exposure (Leiter and Garbe, 2008; MacKie, 2006). It has been shown that multiple
intermittent sun exposures, particularly during childhood, increase the risk of melanoma
occurring (Veierød et al., 2003). Since PAX3 is up-regulated in melanocytes that have been
exposed to UV radiation (Yang et al., 2008), it is possible that PAX3 has a role in the
transformation of melanocytes into melanoma cells.

4

Previous melanoma lesions, numerous benign or abnormal naevi and a family history of
melanoma also lead to an increase in the risk of developing melanoma (Miller and Mihm,
2006). A person’s phenotype, the colour of their hair and the number of naevi they have are
indicators of their risk of developing melanoma. Other phenotypic traits, such as blue eyes,
numerous freckles and red hair are also indicative of a risk of melanoma development due
to inherited variants of the melanocortin receptor 1 (MC1R) (Miller and Mihm, 2006;
Naysmith et al., 2004). The MC1R receptor responds to the binding of α-melanocytestimulating hormone (αMSH) by initiating a signalling cascade that causes an increase in
expression of enzymes that are crucial to melanin production (Frändberg et al., 1998).
Inherited variants of the MC1R receptor can reduce its activity, thus increasing susceptibility
to UV exposure and melanoma (Kennedy et al., 2001).
People with a family history of melanoma due to inheritance of mutations in the familial
melanoma genes cyclin-dependent kinase inhibitor 2A (CDKN2A) or cyclin-dependent kinase
4 (CDK4), both of which are tumour suppressor genes, also have an increased risk of
developing melanoma (Miller and Mihm, 2006). Recently, a microphthalmia-associated
transcription factor (MITF) variant (E318K) has also been implicated in predisposition to
melanoma (Yokoyama et al., 2011). The role of PAX3 in melanoma development has not
been determined to date, but in this thesis we aim to further clarify its role.

2.3

Treatment of melanoma

According to the Australian Cancer Network Melanoma Guidelines Revision Working Party
(2008), TNM stage 0, I and II primary stage melanomas are treated by surgical removal.
Metastatic melanoma lesions of TNM stages III and IV, characterised by lymph node and
distant metastases respectively, are removed by surgery as a first line treatment (Australian
Cancer Network Melanoma Guidelines Revision Working Party, 2008). For inoperable
melanoma, treatment involves chemotherapeutic agents or, less commonly, radiotherapy
(Sondak et al., 2001). Until 2011, chemotherapy drugs included temozolomide (an alkylating
agent) or decarbazine (inhibits cell replication) (Middleton et al., 2000). Interleukin-2, an
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immunological drug that influences T-cell growth, was also used for treatment (Atkins et al.,
1999). These drugs, however, have very low success rates (less than 20%) (Agarwala, 2009).
Emerging new treatments now target the specific mutation associated with cancer
development, making treatment more specific and effective (Amaria et al., 2011; Becker et
al., 2006). For example, one of the most successful new drugs for melanoma treatment
targets a mutation in the BRAF gene, a mutation found in greater than 50% of cases (Amaria
et al., 2011). The BRAF inhibitor Vemurafenib (Roche, Plexxikon), for example, decreases the
activation of the MAPK pathway by inhibiting the mutant BRAF gene (V600), hence
decreasing cell proliferation (Amaria et al., 2011; Davies et al., 2002). In general however,
patients develop resistance to these drugs after 6-9 months (Poulikakos and Rosen, 2011).
Recent research into the development of resistance to Vemurafenib in melanoma cells
suggests that Stat3 and PAX3 are activated by mutant Braf (Liu et al., 2013). Further
research suggests that the Stat3-PAX3 signalling pathway could prove an effective target for
surmounting the resistance to Vemurafenib in melanoma (Liu et al., 2013).

2.4

Introduction to PAX3

The PAX3 gene is at the top of the hierarchy of genes that specify melanocytes. PAX genes
are highly conserved and encode a family of transcription factor proteins having a unique
DNA binding sequence, a 128 amino acid long paired domain (Bopp et al., 1986; Frigerio et
al., 1986). There are nine members of the PAX gene family (PAX1-9) (Chalepakis et al., 1993)
and these are classified into four groups according to whether they possess a full or partial
homeodomain, a second conserved DNA binding domain and an octapeptide. PAX3 belongs
to group III of the PAX genes, i.e. those PAX genes characterised as having both a full
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homeodomain and an octapeptide (Lang et al., 2007; Robson et al., 2006; Walther et al.,
1991).
The proteins encoded by the PAX genes are involved in organogenesis (Chi and Epstein,
2002). One role of the PAX proteins is to maintain the multipotency of “stem” cells while
they proliferate and migrate, until they terminally differentiate into lineage specific cells
that make up several tissues. Mutations in PAX genes are known to result in the formation
of mutant embryos with severe defects. Moreover, PAX genes are commonly expressed in
tumours (Balling et al., 1988; Mansouri et al., 1999). Mutations in the Pax3/PAX3 gene are
known to produce Splotch mice and Waardenburg syndrome in humans (Baldwin et al.,
1992; Henderson et al., 1997; Pingault et al., 2010).
The human PAX3 gene is located at 2q35 and consists of 9 exons and 9 introns, as shown in
Figure 2A. The encoded PAX3 protein is a transcription factor that binds to specific DNA
target sequences on downstream target genes in order to regulate their transcription. The
PAX3 protein contains highly conserved protein domains; a paired domain, a paired-type
homeodomain, a conserved octapeptide and a C-terminal transactivation domain rich in
proline, serine and threonine. The paired domain and homeo-DNA binding domains are
encoded by exons 2 to 4 and exons 5 to 6, respectively, and while they are able to bind DNA
independently, functionally they have an interdependent relationship (Parker et al., 2004;
Strachan and Read, 1994; Underhill and Gros, 1997). The transactivation domain, which
interacts with RNA polymerase to activate or repress transcription, is encoded by exons 7
and 8 (Apuzzo et al., 2004).
The human PAX3 gene gives rise to eight different transcripts due to alternate splicing of the
gene. These transcripts are PAX3A, PAX3B, PAX3C, PAX3D, PAX3E, PAX3G, PAX3H and PAX3I
(also known as PAX3DQ-) (Figure 2B) (Barber et al., 1999). These mRNA transcripts produce
proteins that differ in structure and thus function. The PAX3A and PAX3B isoforms are
derived from exons one through four and encompass the beginning of intron 4, at which
point the protein truncates. These two isoforms do not contain a C-terminal transactivation
domain or a homeodomain (Tsukamoto et al., 1994). The PAX3C transcript includes exon 8
and 5 codons of the beginning of intron 8. PAX3D does not contain intron 8, but continues
through exons 8 and 9 (Parker et al., 2004). PAX3E includes exons 8 through 9, with the 8th
7

and 9th introns spliced out. PAX3G is a truncated isoform of PAX3D, while PAX3H is a
truncated isoform of PAX3E, both lacking exon 8. Neither PAX3G nor PAX3H contain the
entire transactivation domain (Parker et al., 2004). PAX3I is almost identical to PAX3D; the
only difference is the absence of a 5' terminal glutamine at the region encoded by the intron
exon boundary at the beginning of exon 3. As shown by the difference in exons and introns
encoding the varied isoforms of PAX3, it can be seen that the structure of the protein differs
primarily due to the absence of parts or the whole of the transactivation domain and as a
result, the different isoforms have been shown to have different functions (Wang et al.,
2006).
In fact, Wang et al. (2006) showed that the different PAX3 isoforms have different effects on
the behaviour of transfected melanocytes. PAX3A and PAX3B have a negative effect on
melanocyte proliferation. PAX3B also reduces melanocyte migration and increases the rate
of melanocyte apoptosis. PAX3C and PAX3D increase cell proliferation, migration,
differentiation and survival. PAX3E reduces melanocyte proliferation, but increases
apoptosis. PAX3G reduces melanocyte migration and PAX3H increases melanocyte survival,
migration and proliferation. These results show that the PAX3 isoforms have differing
effects on melanocytes and their expression levels and roles in the development of
melanoma remain to be identified.
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A
1553bp
Exon 1

Exon 2

450bp

235

1321

1220

Exon 3

Exon 4

129

678

61347

10696

868

Exon 5

Exon 6

Exon 7

205

165

214

17950

268

Exon 8

Exon 9

477

1557bp

B
367 transcription start
1-451

452-687

*204bp (1022)

688817

818-1489

367 transcription start
1-451

452-687

PAX3a
*33bp (986)

688817

818-1080
135bp

PAX3b

543bp

*266bp (1806)

367 transcription start
1-451

452-687

688817

818-952

953-1158

1159-1324

1325-1539
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Figure 2: The entire PAX3 gene and alternate transcripts. A) The entire PAX3 gene
encompassing exons 1 through 9. B) Eight alternate transcripts, of which seven are
shown, are produced from the PAX3 gene as a result of alternate splicing. The PAX3i
transcript is not present in the image, but contains the same sequence as PAX3d with the
absence of a CAG encoding a glutamine (Q) at the 5' end of exon 3 (indicated by the
arrow). The numbers are indicative of base pairs and an asterisk (*) denotes the stop
codon. Colours are coded to indicate the sequences retained in each alternative mRNA
transcript. The transcripts essentially run from the transcription start site (blue line) to the
stop site (red line), contributing to their differing lengths (Medic and Ziman, 2009).
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Activation of PAX3
PAX3 is activated by two POU family transcription factors, BRN2 and Oct-1 (Berlin et al.,
2012). Only phosphorylated BRN2 activates PAX3 transcription, whereas PAX3 transcription
is repressed in the absence of BRN2 phosphorylation (Pruitt et al., 2004; Zhu and Pruitt,
2005). BRN2 also plays a role in the repression of the MITF promoter (Goodall et al., 2008).
In this way, BRN2 regulates the migration and proliferation of cells of the melanogenic
lineage through the activation of PAX3 by phosphorylated BRN2 and the repression of MITF
through non-phosphorylated BRN2 (Berlin et al., 2012). BRN2 itself can be regulated by
micro RNA, particularly miR-211. This regulation affects the potential of melanoma cells to
invade underlying tissues (Boyle et al., 2011).

2.5

PAX3 in melanocyte development, melanoblast maintenance and
melanogenesis

During mouse embryonic development, Pax3 is expressed in neural and neural crest cells as
early as stage E8.5 (Figure 3) (Goulding et al., 1991). These Pax3 expressing cells arise from
the multipotent stem cells of the neural tube, neural crest and dermomyotome and give rise
to neural cells, skeletal muscle cells and neural crest derived lineages, including pigment
producing melanocytes (Sommer, 2011; Yanfeng et al., 2003).
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Figure 3: The expression of Pax3 as early as stage E8.5 in mouse neural crest cells,
committing them to the melanogenic lineage. PAX3 remains expressed throughout the
development of melanocytes (Medic and Ziman, 2009).

The co-expression of SOX10 in a portion of the Pax3 positive neural crest cells designates
their differentiation along the melanogenic lineage (Sommer, 2011). These neural crest cells
then express markers indicative of melanoblasts; MITF, Kit and Dct (Hou et al., 2000; Steel et
al., 1992), and they migrate toward the developing epidermis, where they terminally
differentiate into melanocytes. At this stage, they express Tyr and Trp-1, which are genes
involved in melanin production (Steel et al., 1992).
Not all melanoblasts, however, become fully differentiated functioning melanocytes
simultaneously. Some of the melanoblasts remain as melanoblasts within the hair follicles in
adult skin, where they function to replace melanocytes that have been lost during the hair
replacement cycle (Nishimura et al., 2002). The PAX3 positive melanoblasts remain at the
base of the arrector pili muscle in the hair follicle in a quiescent state until external factors
cause them to proliferate, differentiate and migrate to take the place of lost melanocytes in
the epidermis (Lang et al., 2005; Nishimura et al., 2002). The PAX3 protein is required to
maintain these melanoblasts in an undifferentiated state, while they remain committed to
the melanocyte cell lineage (Lang et al., 2005). Furthermore, PAX3 continues to be
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expressed in a proportion of epidermal melanocytes of adult skin, presumed to be fully
differentiated, particularly those exposed to UV radiation (Yang et al., 2008).

2.6

PAX3 in cell cycle inhibition and maintenance of stem cells

PAX3 directs the maintenance of an undifferentiated “stem” cell-like state in melanoblasts,
by regulation of apoptosis and cell migration. PTEN and p53 tumour suppressor genes (both
direct targets of PAX3) are inhibited by the PAX3 protein, preventing them from activating
factors that bring about apoptosis during the cell cycle, allowing “stem” cell survival (Furnari
et al., 1998; Van Dyke, 2007). In addition, the BCL2L1 gene is activated by PAX3 and
prevents apoptosis by releasing factors that inhibit apoptotic enzymes (Cheng et al., 2001).
Neural crest derived melanoblasts are thus maintained as undifferentiated cells during
migration to the epidermis. PAX3 regulates migration by spatial and temporal activation of
key migration genes c-Met, NCAM, STX and TGF-β (Epstein et al., 1996; Mayanil et al., 2000;
Nakazaki et al., 2009).
The controversial “cancer stem cell theory” describes a population of cells within the
tumour that, in contrast with stem cells, exhibit the ability to self-renew and propagate, in
addition to having the potential for multidirectional differentiation, resisting apoptosis and
having the ability to enable tumour development, growth and metastasis (Calabrese et al.,
2004; Kucia and Ratajczak, 2006; Reya et al., 2001). Recently, melanoma has been the
subject of debate in regards to the theory of cancer stem cells (Adams and Strasser, 2008;
Klein et al., 2007; Monzani et al., 2007; Schatton et al., 2008; Shackleton et al., 2009).
Furthermore, as described above, PAX3 has been shown to maintain the “stem cell-like”
state of melanocyte precursors and is also expressed in melanoma tumour cells. Thus, there
is the potential for PAX3 to contribute to melanoma development, growth and metastasis
through the maintenance of melanoma cancer stem cells.
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2.7

Downstream target genes of PAX3

As indicated above, PAX3 plays an important role in the development of melanocytes,
particularly in maintenance of undifferentiated melanoblasts and is the main regulatory
gene involved in melanogenesis. Its ability to perform its various roles is achieved by
regulation of a variety of downstream target genes.

Previous research conducted by Medic et al. (2011) showed that PAX3 differentially
regulates downstream target genes in human epidermal melanocytes compared to
metastatic melanoma cells (Figure 4). PAX3 has numerous downstream targets (Barber et
al., 2002; Begum et al., 2008; Bondurand et al., 2000; Lang et al., 2005; Li et al., 2007;
Margue et al., 2000; Nakazaki et al., 2008; Wang et al., 2007; Watanabe et al., 1998). Using a
subset of 14 downstream target genes, based upon their association with processes likely to
be important in melanoma progression, Medic et al. (2011) showed that the promoters of
SOX9 and NES (involved in cell differentiation), TPD52 (cell proliferation), PTEN and TGFβ1
(cell survival) as well as MCAM and CSPG4 (cell migration) were all bound by PAX3 in
melanoma cells, but to a lesser extent or not at all in melanocytes (Figure 4). Furthermore,
the expression of these genes was found to be differentially upregulated in melanoma cells
compared to neonatal melanocytes (Figure 5) (Medic et al., 2011). This fact, together with
the fact that PAX3 is expressed by fewer cells in normal skin, naevi and primary melanoma
cells compared to metastatic melanoma cells (Figure 6) (Medic and Ziman, 2010), implicates
PAX3 and genes regulated by PAX3 in melanoma. The mechanisms underpinning this
differential regulation and expression have not been investigated prior to this research.
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Figure 4: Differential binding by PAX3 to downstream target genes in neonatal human
epidermal melanocytes (HEM1455) compared to metastatic melanoma cells (A2058),
quantified by qPCR. Downstream genes involved in cell differentiation (MITF, DCT, HES1,
SOX9 and NES), cell proliferation (CCNA2, TPD52 and NFKβ2), cell survival (BCL2L1, PTEN
and TGFβ1) and cell migration (MCAM, CSPG4 and CXCR4) were analysed. Enrichment in
PAX3-IP was normalised to input DNA. The fold increase over normalised IgG-IP was then
calculated (Medic et al., 2011).

Figure 5: RT-qPCR analysis of relative expression of downstream target genes of PAX3. A
correlation was found between the binding of PAX3 to each target gene (Figure 4) and
target gene mRNA expression levels (above) (Medic et al., 2011).
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Figure 6: PAX3 expression in naevi, primary melanoma and metastatic melanoma relative
to that of normal skin. The number of cells expressing PAX3 increases from melanocytes
to melanoma cells (Medic and Ziman, 2010).

2.8

Downstream targets of PAX3 differentially regulated in
melanocytes and melanoma cells

Microphthalmia associated transcription factor (MITF)
The key downstream target of PAX3 during melanogenesis, MITF, is involved in melanocyte
differentiation, survival and proliferation. In normal melanocytes, the expression of MITF is
activated by PAX3. Through binding with co-factors CREB and LEF1/β-catenin, PAX3
enhances the transcription of the MITF gene (Figure 7) (Watanabe et al., 1998). The
transcription factor MITF is responsible for controlling the survival, proliferation and
differentiation of melanocytes through activation of melanocytic target genes
(Steingrimsson, 2006). PAX3 activates the expression of MITF in early neural crest cells
leading to the specification of melanoblasts, their migration to the epidermis and to their
proliferation and differentiation into melanocytes. MITF activates the melanogenic cascade
via activation of various downstream targets, including Tyr, Trp-1 and Dct, enzymes
responsible for the final steps of melanogenesis, as well as MelanA and gp100/Silv, which
are structural components of melanosomes (Figure 7) (Yasumoto et al., 1997).
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PAX3 binds the MITF promoter in melanocytes and melanoma cells, however in melanoma
the tight regulation of MITF by PAX3 is lost and MITF is not regulated by PAX3 alone. In
melanoma cells, MITF activation is also by Wnt3a signalling, which causes β-catenin and Lef1
transcription factors to bind to the promoter region of the MITF gene, allowing transcription
to occur (Cook et al., 2005; Takeda et al., 2000b). This alteration in MITF regulation allows
activation of proliferation pathways in melanoma cells (Cronin et al., 2009).

Figure 7: The role of Pax3 in melanogenesis. Pax3 activates MITF, which in turn activates
Silv, Tyr, Melan-A and Trp-1. Pax3 and MITF compete for the promoter of Dct (Medic and
Ziman, 2009).
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Dopachrome tautomerase (DCT)
Dct is involved in differentiation of melanoblasts. During development PAX3 inhibits the
expression of Dct, allowing the melanoblasts to remain in their undifferentiated cell state
(Lang et al., 2005), allowing cells to proliferate, migrate and survive.
The Dct enzyme acts together with tyrosinase and Trp-1 during melanogenesis. Dct causes
dopachrome to be converted to dehydroxyindole-2-carboxylic acid (DHICA)(Figure 8), which
is a precursor of the pigment, eumelanin (Park et al., 2009). Dct is activated by MITF, but
MITF competes with PAX3 to bind to the Dct promoter. In fact, PAX3 has a stronger affinity
for the Dct promoter than MITF (Lang et al., 2005). The displacement of PAX3 by β-catenin,
which is regulated by the Wnt signalling pathway, allows MITF to bind freely to the Dct
promoter, resulting in Dct activation (Figure 9). The inhibition of Dct by PAX3 is important
for the maintenance of melanoblasts during their proliferation and migration to the
epidermis and the hair follicle. Without this inhibition, melanoblasts differentiate into
melanocytes (Lang et al., 2005).

As indicated by Figure 4, DCT is bound by PAX3 in melanoma cells as well and while PAX3
up-regulation leads to DCT gene inhibition and maintenance of a stem cell state in
melanoblasts, this regulation in melanoma cells (Medic et al., 2011) remains to be
determined.

17

Figure 8: The genes involved in melanogenesis. Note that PAX3 is the key regulatory gene
for this process; without PAX3 the entire melanogenic cascade is not activated (Melanoma
Molecular Map Project, 2011). Also note that in this image Dct is referred to as TRP2.

a

b
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Figure 9: The interaction between Pax3, Dct and Wnt. Pax3 inhibits the Dct gene (a),
whereas Wnt causes the inhibition of Pax3 through β-catenin, which displaces Pax3 and
allows Dct transcription (b). Adapted from Lang et al. (2005).

Hairy and enhancer of split-1 (HES1)
HES1 is a basic helix-loop-helix (bHLH) gene encoding a transcription factor repressor
(Kageyama et al., 2000). The primary role of HES1 is to inhibit apoptosis in melanoblasts,
thereby playing a critical role in the survival of these melanocyte precursors (Moriyama et
al., 2006). Additionally, HES1 is expressed in melanoma cells and has been shown to repress
promoter activity of MAP2, a microtubule-associated protein, during melanoma
progression, leading to cell survival (Bhat et al., 2006; Soltani et al., 2005).
SRY (Sex-determining region Y) box 9 (SOX9)
The SOX9 gene belongs to the SOX family of transcription factors. The SOX9 protein is
essential in development, aiding in sex determination and cartilage development (Nakazaki
et al., 2008). More importantly, SOX9 plays a role in the differentiation of melanoblasts into
melanocytes and the production of melanin during melanogenesis (Cook et al., 2005).
Furthermore, SOX9 transcription is regulated by PAX3 (Figure 4) and is upregulated after
exposure to UV radiation by PAX3 (Passeron et al., 2007). SOX9 is bound by PAX3 in
melanoma cells at a significantly higher rate than in melanocyte cells, so it is speculated that
the regulation of SOX9 by PAX3 in melanoma cells may lead to their stem-like phenotype,
particularly of the more metastatic phenotype (Medic et al., 2011).

Nestin (NES)
NES is an intermediate filament expressed predominantly in stem cells of neuroepethelial
lineage. It has been shown to be expressed in stem cells that reside in hair follicles until
these cells mature and NES expression ceases (Amoh et al., 2005). A study conducted by
Ehrmann et al (2005) revealed that malignant melanoma tumours are positive for NES,
whereas benign naevi were NES negative. Its importance here lies in the fact that the
protein is highly expressed in proliferating progenitor and stem cells of neuroectodermal
origin (Brychtova et al., 2006; Redies et al., 1991). The protein ceases to be produced when
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these cells mature, however, it is re-expressed in tumour cells of neuroectodermal (such as
melanoma) and mesenchymal lineage (Ehrmann et al., 2005); and in melanoma it is
presumably regulated by PAX3 (Medic et al., 2011).
Cyclin A2 (CCNA2)
CCNA2 is a cell cycle regulator, required to allow cells to progress from the S phase to the M
phase of the cell cycle (Flørenes et al., 2001; Pagano et al., 1992). In normal melanocytes,
CCNA2 is upregulated after transfection with PAX3 (Wang et al., 2007). Previous research of
PAX3 and its downstream targets demonstrated a low enrichment of the promoter of
CCNA2 in melanocytes, signifying that PAX3 has the potential to regulate melanocyte
proliferation through activation of CCNA2 (Medic et al., 2011).
The binding of PAX3 to the CCNA2 promoter has been shown to occur to a larger extent in
melanoma cells compared to melanocytes (Medic et al., 2011). Furthermore, knockdown of
PAX3 in melanoma cells inhibits cell proliferation and arrests the cell cycle in both the S and
G2/M phases (He et al., 2010). This shows that activation of CCNA2 by PAX3 presumably
contributes to proliferation of both melanocytes and melanoma cells.
Tumour protein D52 (TPD52)
TPD52 is involved in cell proliferation, exerting its effects on the cell cycle at the G2/M
transition phase (Boutros et al., 2004). TPD52 does not show enrichment when analysed by
PAX3-IP in melanocytes, however, it does so in melanoma cells (Figure 4), which suggests
that PAX3 regulates different pathways of proliferation in these two cell types (Medic et al.,
2011). Furthermore, TPD52 overexpression is associated with cell proliferation in cancer,
including in melanoma (Roesch et al., 2007) and the ability of PAX3 to regulate proliferation
of melanoma cells might be through the activation of TPD52.
BCL2-like protein (BCL2L1)
The BCL2L1 gene regulates anti-apoptosis/cell survival during development when cells are
undergoing proliferation (Margue et al., 2000). PAX3 activates the BCL2L1 gene directly in
melanoma cells (Strasser and Youle, 2008) but not in melanocytes (Medic et al., 2011),
presumably reducing apoptosis and increasing cell survival (Margue et al., 2000).
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Furthermore, it has been suggested that PAX3 and BCL2L1 are part of the same pathway
that inhibits apoptosis - the viability of rhabdomyosarcoma cells decreased to a similar
extent when treated with antisense oligonucleotides for PAX3 or BCL2L1 or a combination
of both (Margue et al., 2000).
Phosphatase and tensin homolog (PTEN)
The PTEN gene is a tumour suppressor gene which is responsible for controlling the
progression of the cell cycle by acting on the G1 phase checkpoint. Through p27 Kip1, a cell
cycle inhibitor, PTEN antagonistically regulates the PI3K/AKT signalling pathway (Li and Sun,
1998; Zhou et al., 2003). It is responsible for binding to PIP3 and deactivating it via
dephosphorylation. If PIP3 is not dephosphorylated it can cause the expression of its
downstream target gene Akt, which is responsible for proliferation of cells, anti-apoptosis
and the formation of tumours (Inoue-Narita et al., 2008). Down-regulation of PTEN sees an
increase in activation of Akt, which increases phosphorylation of targets involved in
regulating apoptosis (Cantley and Neel, 1999).
The PTEN protein also prevents growth, migration and invasion of cells via the Shc adaptor
protein and PDGF (Gu et al., 1999). In primary melanoma, less than 15% of cases have a
mutation in the PTEN gene and the loss of a PTEN allele at one locus (loss of heterozygosity)
is shown in 30% to 50% of cases (Reifenberger et al., 1999). However, up to 91% of
metastatic melanoma cases show a decrease or complete absence of PTEN protein
expression (Whiteman et al., 2002). PTEN is bound by PAX3 in melanoma cells, but not in
melanocytes (Figure 4, Medic and Ziman, 2011) and may be down-regulated by PAX3 in
melanoma cells, resulting in a decrease in its function of PIP3 dephosphorylation and
therefore a decrease in tumour suppressor function (Li et al., 2007; Medic et al., 2011).
Essentially, if PAX3 levels rise, PTEN levels decrease and so does its apoptotic role (Li et al.,
2007).
Transforming growth factor beta (TGF-β)
TGF-β is directly regulated by PAX3, but in turn represses PAX3 transcription in a feedback
loop (Yang et al., 2008). TGF-β plays a crucial role in cell-cell adhesion and migration by
regulating genes responsible for modifying the cytoskeleton or adhesion molecules and
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their receptors (Mayanil et al., 2006). TGF-β regulates these cellular properties by activating
Wnt inhibitors, that bring about the alteration of the cytoskeleton and activation of cell
adhesion molecules, increasing the metastatic potential of cells (Yang et al., 2008).
Additionally, neural tube defects are apparent in TGF-β knock-out and Pax3-deficient
Splotch mice, demonstrating that TGF-β is regulated by Pax3 and plays a role in the
migration of precursor cells during development (Sanford et al., 1997). The TGF-β promoter
is bound by PAX3 in melanoma cells to a greater extent than in melanocytes and the
expression of TGF-β is also significantly higher in melanoma cells compared to melanocytes
(Figures 4 and 5, Medic et al., 2011). The implication of an increase in TGF-β is that it could
possibly contribute to melanoma cell migration and metastasis (Hoek et al., 2006; Medic et
al., 2011; Yang et al., 2008).
Melanoma cell adhesion molecule (MCAM)
MCAM is a transmembrane glycoprotein and is a key factor in progression of melanoma
from the radial growth phase to vertical growth phase (Johnson, 1999; Lehmann et al.,
1987; Mills et al., 2002). The MCAM gene encodes a protein involved in cell migration (Xie et
al., 1997). In general, MCAM is not expressed in normal adult epidermal melanocytes, but it
is expressed in melanoblasts of the hair follicle, where it presumably regulates migration to
the epidermis. Moreover, MCAM is directly regulated by PAX3 in melanoma cells to a
significantly higher extent than in melanocytes (Medic et al., 2011). MCAM plays a key role
in melanoma cell migration and adherence to endothelial cells, which also express MCAM
(Figure 10). The activation of MCAM by PAX3 in melanoma cells is thought to play a role in
melanoma cell migration and metastasis (Moh and Shen, 2009; Yoshioka et al., 2003).
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Melanoma cells
crossing the basement
membrane

Figure 10: The interaction between keratinocytes and melanocytes (a) and keratinocytes
and melanoma cells (b). The melanocytes are kept in place due to the attachment to
keratinocytes via cadherin molecules. When the melanocytes transform and proliferate,
they no longer attach to keratinocytes. Instead, they attach to each other through MCAM
molecules. Adapted from Li et al (2003).

Chondroitin sulfate proteoglycan 4 (CSPG4)
The CSPG4 protein is a cell surface proteoglycan that has little to no expression in normal
epidermal melanocytes, but has been associated with melanoma (Campoli et al., 2004).
Increased levels of the proteoglycan CSPG4 have been found in benign and dysplastic naevi
and in both primary and metastatic melanomas (Campoli et al., 2004). CSPG4 contributes to
the adhesion, motility and invasion of tumour cells (Yang et al., 2009). PAX3 binding to
CSPG4 is significantly increased in melanoma cells compared to melanocytes, and its mRNA
levels are significantly increased in melanoma cells (Figures 4 and 5), suggesting that PAX3
may regulate CSPG4, contributing to melanoma cell migration and metastasis (Medic et al.,
2011).
Chemokine (C-X-C motif) receptor 4 (CXCR4)
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CXCR4 is a chemokine receptor that elicits cell migration (Robledo et al., 2001; Rollins,
1997). CXCR4 and its ligand, CXCL12, have been implicated in the migration and positioning
of melanoblasts as well as in the metastatic progress of numerous neoplasms, including
melanoma (Belmadani et al., 2009; Murphy, 2001; Robledo et al., 2001). Research
conducted by Scala et al. (2005) showed a correlation between CXCR4 expression and
unfavourable prognosis in patients with malignant melanoma. PAX3 binds to CXCR4 in
melanoma cells and melanocytes, and there is an increase in CXCR4 mRNA expression in
melanoma cells compared to melanocytes (Figures 4 and 5) (Medic et al., 2011). This
suggests that PAX3 regulation of CXCR4 may result in melanoma cell migration and
metastasis.
All of the aforementioned genes have a role in the proliferation, migration, survival,
differentiation or melanogenic functions of either melanocytes or melanoma cells, or both,
and are all regulated by PAX3, either by inhibition or activation. Several of these genes are
differentially regulated in melanoma cells compared to melanocytes. The mechanism by
which this differential regulation takes place is presumably due to an alteration in the PAX3
gene or protein which affects the activation of its downstream targets. Such changes could
include variation in PAX3 isoform profiles leading to activation or inhibition of different
downstream target genes. Moreover, isoforms may have altered post-translational
modifications, again altering binding to downstream target genes, potentially resulting in
abnormal pathway activation in the cell.

2.9

Post-translational modifications of PAX3

Not only can genes be regulated by alternative splicing, but the proteins produced can also
be modified and controlled through post-translational modifications. Three protein
modifications that commonly occur in cells to regulate protein function are
phosphorylation, acetylation and ubiquitination. These modifications are formed by the
attachment of an organic group to specific amino acid residues, altering the three
dimensional structure and thus the function of the protein.
Phosphorylation of the PAX3 protein, as shown in myogenic cells, results in attachment of a
phosphate moiety to serine residues 201, 205 or 209 (Dietz et al., 2011; Miller et al., 2008).
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Research conducted by Miller and Hollenbach (2007) on mouse primary myoblasts showed
that in the first 24 hours of embryonic muscle cell differentiation the levels of Pax3 protein
decreased, whereas the levels of Pax3 mRNA did not. Labelling with [32P]-orthophosphate
demonstrated that the Pax3 protein was phosphorylated in vivo at serine residues 201, 205
and 209 (Miller et al., 2008). Moreover, the changing pattern of phosphorylation of the
protein at these sites, resulted in the switching of proliferating myoblasts to differentiating
myoblasts (Dietz et al., 2011).
Ichi et al. (2011) showed that the PAX3 protein can be acetylated at lysine (K) residues 437
and 475, and this dramatically affects neural development. Acetylated PAX3 upregulates
Neurog2 expression, resulting in differentiation of neuroblasts into neural cells. Moreover,
acetylated PAX3 downregulates Hes1, thus inhibiting proliferation of these cells (Figure 11).
When PAX3 is deacetylated by SIRT1 (a deacetylase enzyme), there is an up-regulation of
Hes1 and down-regulation of Neurog2, resulting in proliferation of undifferentiated cells.
This shows that acetylation of the PAX3 protein can alter the regulation of downstream
target genes and ultimately cell fate, switching cells from undifferentiated to differentiated
cells (Ichi et al., 2011).

Deacetylated
Pax3
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Figure 11: Acetylation of PAX3 promotes neurogenesis through the activation of Neurog2,
while deacetylation of PAX3 by SIRT1 promotes stem cell proliferation and maintenance
through the activation of Hes1. Adapted from Ichi et al. (2011).

Ubiquitination, the process by which a ubiquitin moiety is attached to a protein, causes it to
have an altered function or be recognised by proteases and degraded. Ubiquitination at
lysine residues involves attachment of a 76 amino acid ubiquitin molecule through the
action of ubiquitin-activating enzyme (E1), cysteine enzyme (E2) and ubiquitin ligase (E3)
(Figure 12) (Kaiser and Huang, 2005). Boutet et al. (2010; 2007) have shown that
monoubiquitination occurs at the PAX3 protein during skeletal muscle development and this
causes the PAX3 protein to be degraded by proteases. This degradation of PAX3 inhibits the
protein from activating pathways that maintain undifferentiated myoblasts, thus allowing
skeletal muscle cell differentiation.

Lysine residue

Figure 12: The process of ubiquitination: Enzymes attach ubiquitin moieties to proteins to
mark them for degradation by proteases. Adapted from Boutet et al (2010; 2007).

Summary:
In this project we aimed to assess whether PAX3/PAX3 is differentially expressed and
differentially modified post-translationally in human melanocyte cells and melanoma cell
lines as this may affect its regulation of downstream target genes and possibly play a role in
driving pathways that lead to transformation of cells.
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3.

Theoretical Framework

PAX3 is expressed in embryonic melanoblasts, melanoblasts in the hair follicle niche, adult
melanocytes (epidermal and follicular) and in naevi and melanoma cells. It is responsible for
regulating pathways involved in cell survival, differentiation, migration and proliferation.
The exposure to UV radiation up-regulates the expression of PAX3 in epidermal
melanocytes. This upregulation of PAX3 results in cells that can survive, proliferate and
migrate. While these are characteristics of developing cells, they are also highly applicable
to cancer cells. PAX3 has been shown to differentially regulate downstream target genes in
melanoma cells compared to melanocytes. This gives us reason to believe that PAX3 is
involved in pathways that lead to melanoma progression and therefore further investigation
is required to examine whether any alterations in the PAX3 gene, its transcript expression
profile or protein modifications lead to alternate roles in melanoma cells compared to
melanocytes, via differential regulation of downstream target genes.
The exact role of PAX3 in adult melanocytes and melanoma cells is not clear. It has been
confirmed that PAX3 has an anti-apoptotic function in melanoma cells and it maintains an
undifferentiated state in melanoblasts, but these might not be the only roles it plays in
epidermal melanocytes and melanoma cells. The purpose of this investigation is to
determine whether there are any differences between melanocytes and melanoma cells in
the PAX3 gene, its splice variants, its encoded protein isoforms or its downstream targets.
Differences in PAX3 transcripts or proteins between melanocytes and melanoma cells could
be harnessed to provide strategies for therapeutic intervention.
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4.

Hypotheses

Previous research has shown PAX3 to differentially regulate downstream target genes in

melanocytes and metastatic melanoma cells. We hypothesised that the differential
regulation of downstream targets could be due to differential expression of PAX3 alternate
transcripts, or differences in post-translational modifications of the PAX3 protein between
melanocytes and melanoma cells. Therefore, PAX3 alternate transcript expression profiles
and

the

presence

of

post-translational

modifications,

particularly

acetylation,

phosphorylation and ubiquitination, were investigated in normal human epidermal
melanocytes and primary and metastatic melanoma cells. Furthermore, using PAX3 silencing
experiments, differential regulation of downstream target genes was confirmed in primary
melanoma cells compared to normal melanocytes and metastatic melanoma cells.

5.

Aims

The aims of this research were:
1. To confirm PAX3 expression and compare levels of mRNA and protein between
neonatal and adult melanocytes and primary and metastatic melanoma cells.
2. To compare PAX3 transcript expression profiles between neonatal and adult
melanocytes and primary and metastatic melanoma cells.
3. To compare post-translational modifications of PAX3 including phosphorylation,
acetylation and ubiquitination, between neonatal and adult melanocytes and
primary and metastatic melanoma cells.
4. To confirm that previously identified downstream target genes are differentially
regulated in neonatal and adult melanocytes relative to melanoma cells lines after
PAX3 silencing in vitro.
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6.

Methods and Materials

6.1

Summary

PAX3 expression was analysed in four groups of cell types - neonatal and adult normal
human epidermal melanocytes and primary and metastatic melanoma cell lines. Six primary
and five metastatic melanoma cell lines were analysed for PAX3 expression to confirm a
similar expression pattern within groups of cell lines. Thereafter, one cell line from each of
the primary and metastatic groups, in addition to neonatal and adult melanocytes, was used
for further analysis throughout the remainder of this research. Cells were stained using
immunocytochemical methods to confirm PAX3 expression. Furthermore, total RNA and
total nuclear proteins were extracted from the cells and levels of PAX3/PAX3 expression
were analysed by real time RT-qPCR and western blot, respectively. To assess PAX3
alternate transcript expression profiles in these four cell types, RNAseq was used. To test for
post-translational modifications of the PAX3 isoforms in the four cell types,
immunoprecipitation and western blot were performed. PAX3 silencing was used to confirm
that PAX3 does in fact differentially regulate downstream targets in the four cell types. The
outcomes of these experiments confirm a differential role of PAX3 in melanocytes and
melanoma cells.
Ethics was granted by the Human Research Ethics Committee at Edith Cowan University
(project number 8375).

6.2

Cell cultures

Human melanoma and melanocyte cell cultures were maintained as a monolayer at 37˚C, in
5% CO2. Metastatic melanoma cell lines (A2058, M14, SKMEL2, SKMEL5 and UACC62) were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% foetal
bovine serum (FBS) (Sigma Aldrich), L-glutamine (300µg/ml), penicillin (400 U/ml) and
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streptomycin (50µg/ml). Primary melanoma cell lines (MM200, MM229, MM329, MM540
and MM622) were maintained in RPMI-1640 media supplemented with 10% FBS and 1%
antibiotics (penicillin and streptomycin), whereas WM115 primary cell line was cultured in
Eagle’s minimum essentials media (EMEM) supplemented with 10% FBS and 1% antibiotics
(penicillin and streptomycin). One representative cell line from the group of primary and
metastatic cell lines was chosen for further investigation. Adult human epidermal
melanocyte primary culture (NHEM-a (P), PromoCell) was maintained in Melanocyte Growth
Media (PromoCell) and adult melanocyte primary culture (NHEM-a (I), Invitrogen) was
maintained in 254 media (Invitrogen). Neonatal human epidermal melanocyte primary
culture (NHEM-n, Promocell) was maintained in Melanocyte Growth Media (PromoCell).
The media was replaced every 48 hours until cells became 80-90% confluent. Cells at
confluency were detached with trypsin/EDTA (Invitrogen). An equal volume of Trypsin
Neutralising Solution (Invitrogen) was added to melanocyte cultures. Trypsin/EDTA used in
melanoma cell line cultures was neutralised using respective media supplemented with FBS.
The cells were then transferred to a falcon tube and centrifuged at 180xg for 7 minutes (for
melanocytes) or 300xg for 5 minutes (for melanoma cells). The supernatant was discarded,
new medium was added and cells were resuspended before being replated. Seeding density
for melanocytes was 8.6 x 103 cells/cm2, and for melanoma cells was 2.8 x 103 cells/cm2.

6.3

RNA extraction

Total RNA was extracted from the cultured cells using the Isolate RNA mini Kit (Bioline)
according to the manufacturer’s instructions. Briefly, cells grown to 80% confluency were
washed with PBS and detached from the flask with trypsin/EDTA. Up to 5x10 6 cells were
transferred into a fresh 10ml centrifuge tube and pelleted by centrifugation at 300xg for 5
minutes (melanoma cells) or 180xg for 7 minutes (melanocytes). 450μl Lysis Solution was
added to cells and mixed thoroughly. Homogenised lysate was placed into a shredding
column which was centrifuged for 2 minutes at 12000rpm. Thereafter, 450μl of 70% ethanol
was added to the flowthrough and the solution was transferred to a spin column and
centrifuged at 12000rpm for 2 minutes. Following two washing steps, the RNA was eluted
from the column in 40μl of RNase-free water and stored at -80⁰C until analysed further.
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The integrity of the RNA was assessed using a Bioanalyser (Agilent 2100). An aliquot of
filtered gel was prepared as per the manufacturer’s instructions. Using the chip priming
station, the gel was loaded onto the chip. 1μL of dye was added to the 12 sample wells and
the ladder well. 1μL of each RNA sample and the ladder were loaded into their respective
wells and the chip was vortexed for 1 minute. The chip was then subject to electrophoresis
and the fluorescence assessed, from which the concentration of RNA was provided in ng/μL,
as was the RNA integrity number (RIN) out of 10, showing the quality of the RNA. Only RNA
with a RIN value above 7 was used.

6.4

Reverse transcription and qPCR

To determine the level of PAX3 mRNA and its downstream targets in all cell lines, RNA was
isolated and reverse transcribed from each cell line and subjected to real time qPCR using an
iQ5 cycler (Bio-Rad). To do this, total RNA was reverse transcribed using the Omniscript RT
kit (Qiagen), according to the instructions. Briefly, 500ng of total RNA (or 200ng for silencing
experiments) was reverse transcribed in a 20μl reaction mixture containing: 1x RT Buffer,
0.5mM dNTP, 1μM Oligo-dT primer (Qiagen), 0.5 units/μL of RNase OUT Recombinant
Ribonuclease Inhibitor, RNase-free water and RNA sample. The reaction was incubated for 1
hour at 37⁰C, followed by 5 minutes at 95⁰C and finally cooled to 4⁰C.
qPCR
1μl of template cDNA, 0.2μM primers and KAPA SYBR FAST qPCR Master Mix
(KapaBiosystems) was used in a final reaction volume of 15μl. Primers used were as follows:
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Table 1: Primers used in RT-qPCR analysis (Medic et al., 2011).
Gene

Forward primer

Reverse primer

GAPDH

5'-TTCTTTTGCGTCGCCAGCCGAG-3'

5'-GTGACCAGGCGCCCAATACGA-3'

PAX3

5'-AGCCGCATCCTGAGAAGTAA-3'

5'-CTTCATCTGATTGGGGTGCT-3'

MITF

5'-CGTCTCTCACTGGATTGGTG-3'

5'-CCGTTGGGCTTGCTGTATGT-3'

DCT

5'-CGACTCTGATTAGTCGGAACTCA-3'

5'-GGTGGTTGTAGTCATCCAAGC-3'

HES1

5'-AGAAAGATAGCTCGCGGCATTCCA-3'

5'-TTCCCCAGCACACTTGGGTCT-3'

SOX9

5'-AGCAAGACGCTGGGCAAGCTCTGG-3'

5'-CCCGTTCTTCACCGACTTCCTCCG-3'

NES

5'-GCGCACCTCAAGATGTCCCTCA-3'

5'-GGTGTTTGCAGCCGGGAGTTC-3'

CCNA2

5'-AGAGGCCGAAGACGAGACGG-3'

5'-TGAATGGTGAACGCAGGCTGTT-3'

TPD52

5'-ACATGGACCGCGGCGAGCAA-3'

5'-GTGGCACTGATCGTGGCAGCAAC-3'

BCL2L1

5'-CAGGTATTGGTGAGTCGGATCGC-3'

5'-GGCTCTCGGCTGCTGCATTGTT-3'

PTEN

5'-GCTGGAAAGGGACGAACTGGTGTA-3'

5'-CACATAGCGCCTCTGACTGGGAA-3'

TGFβ1

5'-GTCACCGGAGTTGTGCGGCA-3'

5'-GCAGTGGGCGCTAAGGCGAA-3'

MCAM

5'-GGGTACCCCATTCCTCAAGT-3'

5'-CTGGGACGACTGAATGTGG-3'

CSPG4

5'-GCCTTCACTGTCACTGTCCTGCCT-3'

5'-TCCTCAGACCCAGAGTCGCCGT-3'

CXCR4

5'-GCCTTCACTGTCACTGTCCTGCCT-3'

5'-AGTCCCCTGAGCCCATTTCCTCG-3'

Binding sites of the PAX3 forward and reverse primers, as well as the expected length of the
product, for each of the PAX3 transcripts are detailed in Figure 13.
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Figure 13: Binding sites for the PAX3 forward and reverse primers on each of the
PAX3 transcripts. The expected product size was 148bp. The reverse PAX3 primer
does not align to PAX3A or PAX3B.

Amplification was performed as follows: Briefly, samples were amplified with a pre-cycling
hold at 95˚C for 3 seconds, followed by 40 cycles of a 2-step protocol (denaturation at 95˚C
for 3 seconds, followed by annealing at 60˚C for 30 seconds). Data acquisition was
performed at the annealing step of each cycle. Melt curve analysis to determine reaction
specificity was included in the protocol with the following additional steps; 1 minute at 95⁰C,
1 minute at 55⁰C followed by 81 cycles with the temperature increasing from 55 by 0.5 ⁰C per
cycle and data collected every 30 seconds. Products were initially analysed by 2% agarosegel electrophoresis and ethidium bromide staining to confirm the production of a single
amplicon of the correct size.
Each sample reaction was performed in triplicate, as biological replicates and included
reagent controls (reagents without RNA or cDNA) and each Ct value was generated from a
standard curve that was produced initially to confirm that each reaction had the same
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efficiency. Reaction efficiency of between 90 and 100% and a correlation coefficient of over
0.99 was considered appropriate for each reaction. The threshold cycle value of the sample
was determined from the standard curve. The mean Ct value of the triplicate for each
sample reaction was used to calculate fold change over GAPDH (ΔCt).
Statistical analysis: Statistical analysis of changes in gene expression in the different cell
lines was performed using a Kruskall-Wallis test. A Kruskall-Wallis test was performed as
these data sets did not exhibit a normal distribution. The house-keeping gene, GAPDH was
used to calculate the fold changes of expression levels. Each gene expression analysis was
performed in triplicate and a mean was taken from these values. A Kruskall-Wallis test was
used to compare the expression of each gene relative to that of GAPDH.

6.5

RNAseq

To assess PAX3 alternate transcript expression profiles, next-generation sequencing for
transcriptome analysis (or RNAseq) was used. Briefly, total RNA was extracted from all of
the representative cell types as previously described (Section 6.3). Library construction and
100bp paired-end sequencing were performed by the Australian Genome Research Facility
(AGRF) Services on Illumina HiSeq2000 systems using 1-10µg of total RNA per sample.
Custom data alignment to the known PAX3 sequences was performed and analysed for
alternative transcript identification.
The Illumina HiSeq2000 method (Figure 14) reads up to 100 base pairs per read. Using the
paired-end method enables the mRNA strand to be read from both directions, with 100
base pair reads from each end giving a reading of 200 base pairs from each strand resulting
in the formation of short fragments of sequenced material. The short read fragments were
then compiled together to form a library. These sequences were then compared to
reference sequences for PAX3 transcripts. Any alternative splicing was identified by
analysing the junction reads of the sequences. RNAseq also allows the expression of each
transcript to be quantified by calculating the amount of junction reads that correspond to
exons of the reference sequence. Thus a data set of PAX3 expression profiles for each
alternate transcript, for each cell type, was constructed.
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The sequence reads generated were cleaned and aligned against the human genome using
the Tophat aligner. Raw gene counts that were mapped to known gene sequences in the
human genome were used to calculate differential gene expression in the samples. The
Cufflinks tool was used to assemble the transcripts and to check for novel transcript
expression. Cuffmerge and cuffdiff were then used to first merge the compared samples and
then analyse differential expression. Expression levels were then calculated as number of
reads per kilobase of exon model per million mapped fragments.

Figure 14: Illumina HiSeq 2000 protocol. Adapted from Gerstein et al. (2009).

6.6

Immunocytochemistry

First, to confirm PAX3 protein expression in the cell lines, immunocytochemistry was
performed as previously described (Medic and Ziman, 2010, 2011). Briefly, 5x104 cells per
cover slip were grown for 24 hours. Cells were fixed in 4% paraformaldehyde and
permeabilised for 15 minutes at room temperature with PBS containing 0.2% Triton-X100
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(0.2% PBST), then blocked with 10% normal goat serum (NGS) in 0.2% PBST for 1 hour. Cells
were stained overnight at 4˚C with mouse monoclonal PAX3 antibody (DSHB) at 1:50
dilution. Excess primary antibody was washed off by rinsing in PBS three times for 5
minutes. This was followed by incubation with anti-mouse IgG conjugated with Dylight-550
for 1 hour. All antibodies were diluted in 0.2% PBST containing 1% NGS. Cover slips were
mounted onto microscope slides with Prolong Gold Antifade Reagent with DAPI (Invitrogen)
in order to stain cell nuclei. Slides were viewed with an Olympus BX41 epi-fluorescent
microscope. Controls with primary antibodies withheld were also included to ensure nonspecific staining was not evident.

6.7

Western blot

To assess the level of expression of PAX3 proteins in the melanoma cell lines and primary
melanocytes, western blot was performed as previously described (Medic et al., 2011). To
extract total cellular proteins from cultured melanoma and melanocyte cells, cells were
washed twice with ice-cold PBS and then scraped from the base of the flask into a solution
of PBS containing protease inhibitor cocktail (PIC, 1x, Roche). Cells were transferred into
individual falcon tubes and centrifuged at 300xg for 5 minutes. Cells were resuspended in
300µl cell lysis buffer (50mM pipes, 85mM KCl, 1% Nonidet P-40, 1x PIC, pH 8.0), briefly
vortexed and incubated on ice for 30 minutes. Cell debris was centrifuged at 10000rpm for 5
minutes at 4˚C and the supernatant (containing cytosolic proteins) was collected and stored
at -80˚C to later analyse by SDS-PAGE alongside the total nuclear protein in order to confirm
the protein extraction procedure was effective in isolating the nuclear proteins of the cells.
The cell pellet was then resuspended in 150µL of nuclear lysis buffer (50mM Tris, 10mM
EDTA, 1% SDS, 1x PIC, pH 8.0), vortexed and incubated on ice for 30 minutes. The samples
were then passed through a 27 gauge needle to aid lysis. The samples were centrifuged at
12000rpm for 10 minutes at 4˚C. The supernatant (containing nuclear proteins) was
transferred to a new tube and stored at -80˚C for further analysis. The pellet (containing
DNA) was discarded.
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The concentrations of extracted proteins were determined using the bicinchoninic acid
(BCA) protein assay kit (Pierce) and absorbance was read using the Fluostar Optima plate
reader.
Cell lysates were diluted to a standard of 20µg (10µg for silencing experiments) with TBS.
Sample reducing agent (4x) and sample buffer (10x) were added to each sample, vortexed
and heated at 70˚C for 10 minutes. The electrophoresis tank was filled with 1x NuPAGE MES
SDS running buffer. Protein samples were loaded onto a NuPAGE Bis-Tris precast 10 well gel
(Life Technologies) alongside 7µL Novex Sharp pre-stained protein standard (Life
Technologies) and the gel was run at constant 400A for 2 hours.
Proteins were transferred from the gel onto nitrocellulose membrane (Biorad) as follows: A
transfer sandwich was assembled under transfer buffer (0.02M Tris, 0.08M Glycine, 0.001M
SDS, 20% methanol). The sandwich was placed into the plastic transfer cassette and then
into the transfer tank. The internal and external sections were filled with transfer buffer and
run at a constant 0.25A overnight at 4°C. After disassembly, the nitrocellulose membrane
was cut for orientation of protein samples and the ladder marked on the membrane.
The Westernbreeze chemiluminescent detection kit (Life Technologies) was used for
immunodetection of the proteins by western blot as per the instructions. The nitrocellulose
membrane was immersed in blocking buffer (Life Technologies) for 30 minutes. The antiPAX3 antibody (mouse monoclonal, DSHB) at working concentration 1:1000 (diluted in
blocking buffer) was added to the nitrocellulose membrane and incubated overnight at 4˚C.
The membrane was washed 4 times at room temperature using the wash buffer provided in
the kit for 5 minutes on a rocking platform. Secondary IgG antibody linked to alkaline
phosphatase, at a working concentration 1:2000, was applied to the nitrocellulose
membrane and incubated for 30 minutes at room temperature on a rocking platform. The
membrane was then washed 4 times, as previously described.
For the immunoprecipitation experiments proteins on western blots were analysed using
the TrueBlot western blot kit (Rockland) as per the instructions. Membranes were washed
with 0.05% TBS-Tween 20 and then blocked using the TrueBlot Blocker provided in the kit
for 2 hours at room temperature. The membranes were washed again with TBS-Tween 20
and incubated with primary antibody in blocking buffer overnight at 4˚C. Primary antibodies
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included anti-human PAX3 (rabbit polyclonal, 1:400, Abcam), anti-acetyl-lysine (rabbit
polyclonal, 1:500, Abcam), anti-phospho-serine (rabbit polyclonal, 1:500, Abcam) and antiubiquitin (rabbit polyclonal, 1:500, Abcam). Membranes were then washed with TBS-Tween
20 and incubated with TrueBlot anti-rabbit IgG secondary antibody (1:1000, Rockland). Blots
were then washed with TBS-Tween 20.
Probed membranes were visualised by chemiluminescence using the substrate provided in
each kit (Westernbreeze and Trueblot). The substrate was mixed according to the kit
instructions and then added to the nitrocellulose membrane and incubated for 5 minutes at
room temperature. The nitrocellulose membrane was sandwiched between transparent
overhead sheets and placed into a cassette. In the dark room, x-ray film (Kodak) was placed
onto the nitrocellulose membrane and exposed for various times (30 seconds, 1 minute, 3
minutes, 5 minutes, 10 minutes and overnight). After exposure, the medical x-ray film was
placed in developer solution for 2 minutes and agitated, washed with water and then placed
in fixer solution for 2 minutes, washed (water) and air dried.
Membranes were then stripped using Restore Western Blot Stripping Buffer (Thermo
Scientific) for 15 minutes and re-probed for β-actin by incubating with anti-actin antibody
(rabbit polyclonal, Abcam, 1:1000) overnight at 4˚C. The western blot was performed using
the anti-rabbit Westernbreeze kit (Invitrogen) and viewed by chemiluminescence as
previously described.
The levels of expression of each protein were assessed by densitometry using the GS-800
Calibrated Densitometer (Biorad), which compares the density of the individual protein
bands in each lane to that of β-actin in the same lane. Each sample was run as a biological
replicate.

6.8

Post-translational modifications of PAX3 proteins (phosphorylation,
acetylation, and ubiquitination)

Immunoprecipitation and western blotting were performed to assess the phosphorylation,
acetylation and ubiquitination status of PAX3 in all cell types, as previously described (Ichi et
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al., 2011). Briefly, cultured cells were lysed and nuclear proteins extracted as described
above in section 6.7. PAX3 proteins were immunoprecipitated with mouse monoclonal antiPAX3 antibody (DSHB, 10µg/ml), which recognises the C-terminus region of the protein, or
rabbit polyclonal (Abcam, 2.5µg/ml) or goat polyclonal (Abcam, 2.5µg/ml) antibody, which
both recognise the common N-terminus of each of the PAX3 isoforms. The antibody/antigen
complex was immunoprecipitated using protein A (for mouse and rabbit antibodies) or G
(for goat antibody) magnetic Dynabeads (Life Technologies) or anti-IgG (for rabbit antibody)
agarose beads (Rockland). Both direct and indirect methods of immunoprecipitation were
performed to determine the most optimal procedure. The direct method involved
incubating the immunoprecipitating antibody (mouse monoclonal anti-PAX3 (DSHB), rabbit
polyclonal anti-PAX3 (Abcam) or goat polyclonal anti-PAX3 (Abcam)) with the appropriate
beads (protein A or G magnetic Dynabeads (Life Technologies), rabbit anti-IgG agarose
beads (Rockland)) for 30 minutes at room temperature. For immunoprecipitation using
protein A or G magnetic beads, the antibodies were cross-linked to the beads using BS3
cross-linking agent (Thermo Scientific) for 15 minutes at room temperature before
incubating the bead/antibody complex with the protein sample. The indirect method, using
the same antibodies and beads, included incubating the antibody with the protein first, then
incubating the antibody/protein complex with the beads.
Beads were washed in 250µL 1xPBS and centrifuged at 2500xg for 2 minutes (centrifugation
was for agarose beads only). Proteins were eluted from the bead/antibody complex by
heating samples at 70˚C for 10 minutes with 20µL glycine elution buffer (glycine buffer was
used for magnetic beads only), sample reducing agent (1x) and sample buffer (1x) and then
the mixture was run on a NuPAGE Bis-Tris precast gel. The following antibodies were used
for western blotting: anti-PAX3 (mouse monoclonal, DSHB, 1:1000), anti-phosphoserine
(rabbit polyclonal, Abcam, 2.5µg/ml), anti-acetyl-lysine (rabbit polyclonal, Abcam, 2.5µg/ml)
and anti-ubiquitin (rabbit polyclonal, Abcam, 2.5µg/ml). Similarly, immunoprecipitation was
performed with the anti-phosphoserine, anti-acetyl-lysine and anti-ubiquitin antibodies and
anti-PAX3 (mouse monoclonal, DSHB, 1:1000) was used to probe the membrane (or
precipitated proteins). Table 2 outlines important information regarding the binding sites
and suppliers of the antibodies used throughout the western blot and immunoprecipitation
procedures.
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Table 2: The amino acid epitopes and catalogue numbers for the antibodies used in
western blot and immunoprecipitation procedures throughout this project.
Antibody

Supplier

Catalogue

Binding site/s

Number

PAX3 transcripts
recognised by
antibody

Anti-human PAX3
(mouse),

Amino acids
DSHB

N/A

298-481,

monoclonal

C-terminal region

Anti-human PAX3

Amino acids

(rabbit),

Abcam

ab50193

181-230,

polyclonal

N-terminal region

Anti-human PAX3

Amino acids

(goat),

Abcam

ab15717

2-12,

polyclonal

N-terminal region

Anti-acetyl lysine

Acetylated lysine residues on

(rabbit),

Millipore

AB3879

proteins

PAX3C-PAX3E

PAX3C-PAX3H

PAX3A-PAX3H

N/A

polyclonal
Anti-phosphoserine
(rabbit),

Phosphoserine,
Millipore

AB1603

peptidylphosphoserine, serine-

polyclonal

phosphorylated proteins

Anti-ubiquitin

Ubiquitin and ubiquitinated

(rabbit),

Millipore

07-375

proteins

polyclonal

40

N/A

N/A

6.9

PAX3 silencing and analysis of PAX3 downstream targets in
melanoma cell lines and primary melanocytes

To assess whether PAX3 does indeed regulate the selected downstream target genes, PAX3
was silenced using siRNA and RT-qPCR was performed using the primers provided in Table 1.
The genes studied (Table 1) were chosen based on data showing them all to be regulated by
PAX3, as well as being expressed in melanocytes and melanoma cells.
Knock-down of all PAX3 transcripts was accomplished using pre-designed PAX3-specific
Silencer Select siRNA (s10059 and s224172, Ambion), and Lipofectamine 2000 Transfection
Reagent (Life Technologies) following the manufacturer’s recommendations. Briefly, 1x105
(for melanoma cells) or 2x105 (for melanocytes) cells were seeded in a six-well plate 24
hours prior to transfection with 10nM of PAX3-specific siRNA (s10059 and s224172
individually, or in combination), or negative control siRNA (Negative Control #1 siRNA,
Ambion) using RNAiMAX Transfection Reagent (Ambion). Each silencing experiment also
included positive control, transfection with Silence Select GAPDH siRNA (Ambion), as well as
non-treated cells. Efficient PAX3 knock-down was confirmed after 24, 48 and 72 hours posttransfection by RT-qPCR and western blot as previously described (section 6.7). The changes
in the expression of previously identified PAX3 targets, following its knock-down, were then
analysed by RT-qPCR and quantified by calculating the fold change (∆∆Ct) of the gene, first
relative to 18S (∆Ct) and then to the negative control siRNA (∆∆Ct). A threshold of greater
than 70% knockdown of GAPDH and PAX3 using siRNA was considered a valid knockdown
(Hsieh et al., 2004; Krueger et al., 2007). Each silencing experiment was performed in
duplicate using biological replicates.
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7.

Results

A panel of five metastatic and six primary melanoma cell lines, one neonatal and two adult
melanocyte cultures were analysed for PAX3 expression. The levels of PAX3 mRNA and PAX3
protein were assessed in each cell line using RT-qPCR, immunocytochemistry and western
blot. One representative cell line from the primary and metastatic melanoma groups was
chosen for further analysis of PAX3 transcript expression profiles and for analysis of PAX3
post-translational modifications and downstream targets. To identify differences in PAX3
expression between melanocytes and melanoma cells that would explain the previously
observed differences in regulation of downstream target genes, RNAseq was used to
compare expression profiles of PAX3 transcripts, whereas immunoprecipitation was
performed to test for differences in post-translational modifications of the PAX3 protein
isoforms. Finally, PAX3 silencing was used to confirm differences in the regulation of known
downstream target genes between primary and metastatic melanoma cells and neonatal
and adult melanocytes.

7.1

Clarifying consistency of PAX3 expression within groups of cell lines

7.1.1 PAX3 expression analysed by immunocytochemistry

Figure 15 shows the expression of PAX3 in a panel of primary and metastatic melanoma cell
lines and in neonatal and adult primary melanocyte cell cultures. Mouse anti-PAX3 (DSHB,
1:50) primary antibody followed by anti-mouse IgG-550 (Dylight, 1:500) secondary antibody
were used to stain PAX3 protein. Nuclei were stained with DAPI to confirm nuclear
localisation of PAX3 in all cell types.
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Immunocytochemistry results show that PAX3 is expressed in all of the melanoma cell lines
and both neonatal and adult melanocytes (Figure 15). Furthermore, 90-95% of cells were
PAX3 positive in all cell types.
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Metastatic melanoma cells

Melanocytes

PAX3

DAPI

DAPI

A2058

NHEM-a

M14

SK-MEL-2

SK-MEL-5

UACC62

Negative control

NHEM-n

Primary melanoma cells

PAX3

PAX3

DAPI

MM200

MM229

MM329

MM540

MM622

WM-115

Figure 15: Immunocytochemistry of neonatal and adult human epidermal melanocytes, five metastatic melanoma cell lines and
six primary melanoma cell lines. Nuclear PAX3 protein expression (red) is observed in all melanoma cell lines and primary
melanocytes. Cell nuclei are stained with DAPI (blue). The scale measures 100µM. A negative control was included with each
experimental run and proved negative in each instance.
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7.1.2 PAX3 expression analysed by Reverse-Transcriptase Polymerase
Chain Reaction (RT-qPCR)
In order to quantify PAX3 mRNA expression, RT-qPCR was performed in all primary and
metastatic melanoma cell lines and neonatal and adult primary melanocytes (Figure 16).
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Figure 16: RT-qPCR was performed on six primary and five metastatic cell lines and
neonatal and adult normal human epidermal melanocytes. The relative level of expression
of PAX3 compared to housekeeping gene GAPDH was calculated by the ∆∆Ct method. All
PCRs were performed in triplicate for each of two biological replicates and average values
were used to calculate fold change over GAPDH for each sample. All samples were run in
biological duplicates and the average fold change values are calculated and presented in
the graph. The error bars represent the standard deviation of the biological replicates.
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Figure 16 represents the relative expression of PAX3 for each of the primary melanoma cell
lines (MM200, MM229, MM329, MM540, MM622 and WM115), metastatic melanoma cell
lines (A2058, M14, SKMEL2, SKMEL5 and UACC62) neonatal human epidermal melanocytes
(NHEM-n) and adult human epidermal melanocytes (NHEM-a (P) and NHEM-a (I)). A MannWhitney U test was utilised to determine whether there was a significant difference in PAX3
mRNA expression between cell lines of the same cell type. The primary cell line with a
significantly lower PAX3 expression than the others was MM622 (p= 0.007). Additionally,
the M14 cell line exhibited a significantly higher expression of PAX3 mRNA than the other
metastatic melanoma cell lines (p= 0.007).
To statistically compare the relative expression levels per cell type, a test for normality was
performed, but indicated that the data was not normally distributed, thus a non-parametric
Kruskal-Wallis test was required for further statistical analysis. Upon comparison of relative
PAX3 expression between primary melanoma, metastatic melanoma and melanocyte groups
using the Kruskal-Wallis test, a significant difference in PAX3 mRNA levels was found
between groups (p=0.035). In order to determine which of the groups were significantly
different from the others, Mann-Whitney U tests were performed. Whereas the levels of
PAX3 mRNA in the primary melanoma group of cell lines were not significantly different
from those in the metastatic group of cell lines (p=0.644), there was a significant difference
in mRNA levels between primary melanoma cells and melanocytes (p=0.001). There was a
significant difference in PAX3 mRNA levels between the metastatic group of melanoma cell
lines and the melanocytes (p=0.002) (Table 3). Furthermore, it was found that there was a
significantly higher expression of PAX3 in the adult melanocytes, both NHEM-a (P) and
NHEM-a (I), compared to the neonatal melanocytes (p=0.006, p=0.004, Table 3).
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Table 3: mRNA levels of PAX3 in melanocytes, primary melanoma cells and metastatic melanoma cells

Melanocytes
Cell line/culture
-3

Mean fold change (x10 )
-3
Std dev (x10 )
Between group
p-values
(Kruskal-Wallis test)

NHEM-n
52.16
±22.33

NHEM-a
(P)
909.28
±56.65

Primary melanoma
NHEM-a
(I)
208.84
±5.31

Melanocytes v Primary
melanoma: p= 0.001*

Metastatic melanoma

MM200

MM229

MM329

MM540

MM622

WM115

A2058

M14

SKMEL2

SKMEL5

UACC62

13.09
±7.33

1.99
±0.20

5.01
±2.55

8.68
±4.14

1.10
±0.09

6.35
±0.05

4.51
±3.09

22.95
±16.15

10.97
±7.15

3.32
±1.22

3.59
±2.27

Primary melanoma v Melanocytes: p= 0.001*

Metastatic melanoma v Melanocytes: p= 0.002*

Primary melanoma v Metastatic melanoma: p= 0.644

Metastatic melanoma v Primary melanoma: p= 0.644

Melanocytes v Metastatic
melanoma: p= 0.002*

*Statistically significant, p ≤ 0.05
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7.1.3 Western blot
Western blot was used to determine the relative levels of PAX3 protein in all cell types. For
each sample, a standard amount of protein (20µg total nuclear protein) was loaded onto the
gel. The levels of PAX3 protein in each of the six primary melanoma cell lines, five metastatic
melanoma cell lines, one primary neonatal melanocyte culture and two adult melanocyte
primary cultures were assessed.

Figure 17: Western blot results. Each sample was run in duplicate on each of two
biological replicates on separate gels and blotted against PAX3 (DSHB, 1:1000) and β-actin
(Abcam, 1:1000). The representative western blots are shown here.

The western blot (Figure 17) revealed a single band when blotted with anti-PAX3 antibody
(mouse monoclonal, DSHB) of around 55kDa. This corresponds to isoforms PAX3C, D and/or
E which are 53kDa, 53kDa and 56kDa, respectively. Furthermore, primary melanoma cell
line WM115 also showed a band around 44kDa, which could correspond to isoforms PAX3G
or PAX3H. PAX3 protein levels were assessed by densitometry to quantitatively assess
expression levels relative to that of β-actin and the average fold change above that of βactin for each sample was graphed (Figure 18).
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Figure 18: PAX3 protein expression relative to β-actin expression. Each sample was run in
duplicate on separate gels and the density of each band was assessed by densitometric
scanning using the GS-800 Calibrated Densitometer (Biorad). The density of each PAX3
band was compared to that of the housekeeping gene β-actin for each lane on the same
membrane and the fold change calculated and graphed. The error bars represent the
standard deviation between duplicate samples.

Densitometry results were normalised to the background and PAX3 protein expression was
calculated relative to β-actin. The data were normally distributed and so a one-way ANOVA
was used to compare relative PAX3 protein expression levels between groups. There was no
significant difference in relative PAX3 protein expression between the primary melanoma
cell lines, metastatic melanoma cell lines or melanocytes when the groups were compared
using a one-way ANOVA test (p= 0.088, Table 4). Furthermore, a student’s T-test was used
to determine whether there was significant difference in PAX3 protein expression within
each of the groups. There was no significant difference in relative PAX3 protein expression
between the primary melanoma cell lines, however, within the metastatic melanoma cell
line panel, PAX3 protein was significantly higher in M14 than in A2058, SKMEL5 and UACC62
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(p= 0.037, p= 0.035 and p= 0.032, respectively). Comparison of PAX3 protein expression
within the melanocyte cells showed no statistically significant difference. These results differ
considerably to the results obtained from qPCR analysis of mRNA expression, where the
PAX3 mRNA expression in adult melanocytes was significantly higher than that found in the
primary and metastatic melanoma cell lines and neonatal melanocytes.
Primary melanoma cell line MM540 and metastatic melanoma cell line M14 were chosen for
further comparative experiments along with neonatal (NHEMn) and adult (NHEMa (I))
primary melanocyte cultures.
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Table 4: Protein levels of PAX3 in neonatal and adult melanocytes and primary and metastatic melanoma cells

Melanocytes
Cell line/culture

NHEMn

Mean and standard
deviation

1.415
±0.254

Between group
p-values
(one-way ANOVA)

NHEMa
(P)
1.369
±0.257

Primary melanoma
NHEMa
(I)
1.700
±0.149

Melanocytes v Primary
melanoma: p= 0.331

Metastatic melanoma

MM200

MM229

MM329

MM540

MM622

WM115

A2058

M14

SKMEL2

SKMEL5

UACC62

1.405
±0.283

0.857
±0.136

1.179
±0.195

1.632
±0.162

1.543
±0.292

1.063
±0.013

1.417
±0.034

1.730
±0.046

1.487
±0.028

1.145
±0.020

1.359
±0.028

Primary melanoma v Melanocytes: p= 0.331

Metastatic melanoma v Melanocytes: p= 0.901

Primary melanoma v Metastatic melanoma: p= 0.482

Metastatic melanoma v Primary melanoma: p= 0.482

Melanocytes v Metastatic
melanoma: p= 0.901
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7.2

RNAseq to assess differential expression of PAX3 transcripts

One representative cell line from each of the melanoma cell groups, as well as one neonatal
and adult melanocyte primary culture, were analysed by RNAseq for relative PAX3 transcript
expression profiles. Total messenger RNA from metastatic melanoma cell line M14, primary
melanoma cell line MM540, neonatal normal human epidermal melanocytes (NHEMn) and
adult normal human epidermal melanocytes (NHEMa, Promocell) was sequenced using
paired end sequencing on the Illumina HiSeq2000 platform at the Australian Genome
Research Facility.
Primary data analysis was conducted by the Australian Genome Research Facility. Primary
sequence data was generated using the Illumina CASAVA 1.8.2 pipeline as a FASTQ format.
Cleaned sequence reads were aligned against the human genome using the Tophat aligner
and transcripts were assembled with the Cufflinks tool using the reference annotation based
assembly (RABT) option. Differential expression of the PAX3 transcripts was then analysed
through the use of Cufflinks applications Cuffmerge and Cuffdiff, merging the two samples
for comparison and assessing the differential expression of the transcripts. Each of the
transcript expression levels were normalised to the highest expressed transcript level and
the fold change for each transcript and significant difference of transcript expression
between cell types was calculated.
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Figure 19: A comparison of PAX3E expression levels between neonatal and adult
melanocytes and MM540 and M14 melanoma cell lines measured as number of reads per
kilobase of exon model per million mapped fragments. Asterisk (*, **) denotes significant
difference. No significant difference was found between neonatal melanocytes and the
primary or metastatic melanoma cell lines.

Adult melanocytes were compared against neonatal, primary and metastatic melanomas.
The only PAX3 transcript shown to exhibit significant differential expression between cell
types was PAX3E, which was significantly downregulated in primary and metastatic
melanoma cells compared to adult melanocytes (Figure 19), with a significant fold change of
4.28 between metastatic melanoma cells (M14) and adult melanocytes (NHEMa) (p<0.001),
and a significant fold change of 4.58 between primary melanoma cells (MM540) and adult
melanocytes (NHEMa) (p<0.001). There was no statistically significant difference between
PAX3 transcript expression profiles between neonatal and adult melanocytes.
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7.3

Testing for post-translational modifications

7.3.1 Optimisation of immunoprecipitation procedure
In order to ensure optimal immunoprecipitation procedures, a number of optimisation
conditions were trialled in order to find the most effective immunoprecipitation method.
Optimisation steps included testing direct versus indirect methods, the use of different antiPAX3 antibodies, different temperatures for antibody-antigen binding, as well as different
incubation times, and different immunoprecipitation beads.
As indicated below, the direct immunoprecipitation procedure failed to capture the PAX3
protein, evident from the bands present in the lane containing the supernatant (lanes 3, 5, 7
and 9), whilst no bands were present in the lanes containing the immunoprecipitated
sample (lanes 2, 4, 6 and 8, Figure 20A). Furthermore, it was not possible to determine
whether PAX3 was immunoprecipitated by the indirect procedure due to the presence of
the antibody heavy chains at 50 kDa, which could mask the presence of PAX3 protein at 56
kDa (lanes 2, 6 and 8, Figure 20B). It was apparent, however, that any of the three bead
types (ChIP, protein A or protein G) could be used in further immunoprecipitation
experiments, as they produced the same result, or lack of it (lanes 2-5 and 6-9, Figure 20B).
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Figure 20: Optimisation of the immunoprecipitation procedure using direct (A) and
indirect (B) procedures. Temperature (4˚C) and incubation times (overnight) were kept
constant. Anti-PAX3 antibodies raised in mouse and goat were used and ChIP beads and
protein A (mouse) and G (goat) beads were also tested. The supernatant (the flowthrough that was collected after incubation of the beads, antibody and protein) was run
alongside each immunoprecipitation sample to determine whether the PAX3 antibody
sufficiently immunoprecipitated the PAX3 protein. mPAX3, rPAX3 and gPAX3 = PAX3
antibody raised in mouse, rabbit and goat respectively. IP = immunoprecipitation, Sup. =
supernatant.

Due to the presence of multiple bands in the indirect immunoprecipitation procedure, the
direct

method

was

used

to

determine

the

optimal

concentrations

of

the

immunoprecipitating antibody (using mouse, rabbit and goat anti-PAX3 antibodies).
Concentrations of 1μg and 10μg of antibody were used along with protein A (mouse and
rabbit) and protein G (goat) coated Dynabeads (Invitrogen) to immunoprecipitate PAX3.
Again, the result showed that PAX3 was not being pulled out of the total nuclear proteins by
the bead and antibody complex, despite changing the concentration of the antibody (Figure
21).
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Figure 21: Optimisation of the direct immunoprecipitation procedure using different antiPAX3 antibody concentrations (1μg or 10μg) to immunoprecipitate the PAX3 protein.
Protein A (mouse and rabbit) and protein G (goat) Dynabeads were used for
immunoprecipitation. mPAX3, rPAX3 and gPAX3 = PAX3 antibody raised in mouse, rabbit
and goat respectively. IP = immunoprecipitation, Sup. = supernatant.

Due to the absence of PAX3 protein in the lanes containing the immunoprecipitated sample
when the direct method was used, it was clear that the indirect method should be used for
further optimisation. Further experiments were conducted using anti-PAX3 antibodies
raised in different species for immunoprecipitation and western blot (Figure 22A). Antibody
heavy and light chains appear when only the antibodies were used in the
immunoprecipitation procedure, without cellular protein (lanes 2-7, Figure 22B). The flow
through from washing after incubation of the antibody and antigen was also included on the
gel in order to determine whether the antibody was binding the PAX3 protein but detaching
during washing (lanes 5 and 8, Figure 22A).
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Figure 22: Optimisation of the immunoprecipitation procedure. A) Immunoprecipitation
was performed using anti-PAX3 (goat) and immunoblotted with anti-PAX3 (rabbit) to
attempt to eliminate antibody heavy chain interference, however, results indicate crossreactivity between species. Additionally, a band appears at 44kDa in the input when
blotted with anti-PAX3 raised in rabbit, which corresponds to isoforms PAX3G and PAX3H
(lane 2). B) Anti-PAX3 antibodies (mouse (m) (lanes 2 and 3), rabbit (r) (lanes 4 and 5) and
goat (g) (lanes 6 and 7)) were subject to the IP procedure, without cellular protein, and
blotted with mouse anti-PAX3 to determine where antibody heavy and light chains
appeared on the gel to allow us differentiate between antibody IgG and our PAX3
product. mPAX3, rPAX3 and gPAX3 = PAX3 antibody raised in mouse, rabbit and goat
respectively. IP = immunoprecipitation, Sup. = supernatant; F/T = flow through.

For these reasons, after extensive optimisation of the immunoprecipitation procedures, the
indirect method was chosen for all further analyses, along with anti-PAX3 raised in rabbit as
the immunoprecipitating antibody and anti-PAX3 raised in mouse as the immunoblotting
primary antibody, due to its lower background. Anti-PAX3 raised in mouse was unable to be
used as the immunoprecipitating antibody as it produced multiple bands when
immunoblotted with anti-PAX3 raised in both rabbit and mouse.
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7.3.2 Immunoprecipitation and western blot
Total nuclear proteins were extracted from the metastatic cell line, M14, and the primary
melanoma cell line, WM115, as well as from neonatal (NHEMn) and adult (NHEMa (I))
melanocytes, and subject to immunoprecipitation using anti-acetyl lysine, antiphosphoserine and anti-ubiquitin antibodies, respectively. Mouse anti-PAX3 antibody was
then used to blot the membranes to determine if PAX3 was included in the proteins that
were acetylated, phosphorylated or ubiquitinated.

Figure 23: Immunoprecipitation (IP) using anti-acetylysine (AL), anti-phosphoserine (PS)
and anti-ubiquitin (Ub) immunoblotted with anti-PAX3 (mouse monoclonal, DSHB) in the
metastatic melanoma cell line M14 (A), the primary melanoma cell line WM-115 (B), adult
human epidermal melanocytes (NHEM-a (I)) and neonatal human epidermal melanocytes
(NHEM-n) (C). Figure 23D shows the presence of a 44kDa product using M14 cell lysate
and immunoblotting with mouse anti-PAX3 antibody (DSHB). Al= acetylated, PS =
phosphorylated, Ub = ubiquitinated; mPAX3, rPAX3 and gPAX3 = PAX3 antibody raised in
mouse, rabbit and goat respectively. IP = immunoprecipitation, Sup. = supernatant.
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Post-translational modifications of PAX3 were analysed in the metastatic cell line M14
(Figure 23A). Lane 1 contains M14 total nuclear protein input, blotted using anti-PAX3
(mouse monoclonal, DSHB) for comparison with other sample lanes. Each precipitating
antibody (anti-PAX3, anti-acetylysine, anti-phosphoserine and anti-ubiquitin) was run
alongside its respective immunoprecipitation (IP) sample to confirm the presence of the
desired product relative to the presence of antibody heavy chains (at approximately 50kDa).
Lanes 3, 5, 7 and 9 contain the immunoprecipitated PAX3 protein, acetylated proteins,
phosphorylated proteins and ubiquitinated proteins, respectively. The membrane was then
blotted for PAX3 and, after ruling out the product being the heavy chain of the antibody, it
can be seen that a product that measures approximately 56kDa is present in each of the
immunoprecipitation lanes, which could correspond to PAX3 isoform E (56 kDa), or
potentially PAX3C and/or D (53 kDa). This result suggests that these isoforms are acetylated,
phosphorylated and ubiquitinated in the M14 metastatic melanoma cell line.
PAX3 protein from the primary melanoma cell line, WM-115, was also tested for acetylation,
phosphorylation and ubiquitination using the respective antibodies, as described above. As
shown in Figure 23B, upon immunoprecipitation with the anti-acetyl lysine, antiphosphoserine and anti-ubiquitin antibodies and imunoblotting with anti-PAX3, a product of
44kDa, corresponding to the expected size of PAX3g and PAX3h isoforms, suggests that
these isoforms are possibly acetylated, phosphorylated and ubiquitinated in primary
melanoma cell line WM115, whereas a band of 56kDa was not detected.
Furthermore, PAX3 acetylation, phosphorylation and ubiquitination were assessed in both
the adult primary melanocytes and the neonatal primary melanocytes (Figure 23C). Again, a
product of 44kDa is present in each of the samples, whereas a band of 56kDa was not
detected, suggesting that PAX3g or PAX3h are acetylated, phosphorylated and ubiquitinated
in normal human epidermal melanocytes. Although a 44kDa band is not detected in the
input in Figures 23B and 23C, previous western blot results have detected a product of
44kDa in the input using the mouse anti-PAX3 monoclonal antibody when exposed for a
longer period of time (e.g. Figure 23D).
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Interestingly, it appears that there is the possibility of different isoforms of the PAX3 protein
being differentially post-translationally modified in the metastatic melanoma cell line
compared to those of the primary cell line and neonatal and adult melanocytes.

7.4

PAX3 silencing and downstream targets

PAX3 silencing was used to confirm the differential regulation of previously identified
downstream target genes by PAX3 in primary and metastatic melanoma and adult and
neonatal melanocytes. The expression levels of each of the downstream target genes were
calculated by normalising the Ct value of the gene to that of 18S (ΔCt). The fold change in
siPAX3 was then calculated relative to the negative control siRNA sample (ΔΔCt), and
converted to a percentage, and this was performed for each of the four cell types over the
course of a three day silencing experiment. The knockdown experiment included GAPDH
silencing as a positive control to ensure that the procedure was effective (Figure 24). Once
the efficacy of the procedure was confirmed, PAX3 silencing was performed on neonatal
and adult melanocytes and primary and metastatic melanoma cells and downstream target
gene expression was analysed by qPCR.
Figure 24 shows a dramatic knockdown of GAPDH in primary melanoma (WM115) (>98%)
and metastatic melanoma (M14) (>78%) cells following treatment with GAPDH siRNA,
indicating that the knockdown procedure was effective in these two cell lines. PAX3 was
also sufficiently silenced in the primary melanoma cells (>75%), however, knockdown of
PAX3 in the metastatic melanoma cells was not efficient following treatment with PAX3
siRNA (<56%). Primary melanocyte cultures did not show efficient knockdown of either
GAPDH or PAX3 after treatment with siRNA, with adult melanocytes showing <50%
knockdown of GAPDH levels and <52% knockdown of PAX3 levels, and neonatal
melanocytes showed <57% and <40% GAPDH and PAX3 knocked down, respectively.
Although the knockdown procedure was not considered efficient for the adult and neonatal
melanocyte cultures (with knockdown of GAPDH <70%), remaining PAX3 expression was
significantly lower than negative controls in all cell types following treatment with siPAX3
and therefore downstream target gene expression was analysed further.
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Figure 24: Percentage of remaining mRNA expression of PAX3 following silencing with siPAX3 and GAPDH following silencing
with siGAPDH in adult melanocytes, neonatal melanocytes, primary melanoma cells and metastatic melanoma cells.
Percentage of remaining mRNA expression was calculated relative to 18S and then as fold change relative to the negative
control (NC) siRNA and converted to a percentage. si DAY 1, 2, 3 = Day 1, 2, 3 of GAPDH or PAX3 silencing experiments; si
DAY 1, 2, 3 NC = Day 1, 2, 3 of negative control silencing experiments run in parallel to GAPDH and PAX3 silencing. Each
silencing experiment was performed in duplicate using a biological replicate.
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7.4.1 Expression levels of PAX3 downstream targets involved in
cell differentiation following PAX3 silencing

Figures 25-28 represent the percentages of remaining mRNA expression of PAX3 and those
of its downstream target genes relative to the negative control in each of the four cell types,
after knockdown of PAX3 with siRNA. Percentage of remaining expression was analysed by
RT-qPCR at 24, 48 and 72 hours following transfection with siRNA to silence PAX3.
Following transfection of cells from all cell types with PAX3 siRNA, PAX3 was shown to be
significantly (but not efficiently) decreased post-knockdown in neonatal (NHEMn, p=0.045)
and adult (NHEM (I), p=0.046) melanocytes, and in primary (WM115, p<0.05) and metastatic
(M14, p=0.020) melanoma cells (Figure 25).
Furthermore, MITF was shown to be downregulated in neonatal melanocytes after PAX3
siRNA transfection (p=0.027) and in the primary and metastatic melanoma cell lines
(p=0.004; p=0.033, respectively). Although MITF expression levels in adult melanocytes
were not significantly reduced following PAX3 silencing, there is a trend toward lower MITF
expression levels post-silencing. DCT also exhibited a significant and striking decrease in the
primary metastatic cell line only following silencing of PAX3, (p<0.05). NES is significantly
downregulated in primary melanoma cells after PAX3 silencing (p=0.029), and, HES1
expression is downregulated only in neonatal melanocytes after transfection with PAX3
siRNA (p=0.017) (Figure 25). These findings indicate that differentiation genes are not
generally affected by PAX3 in metastatic melanoma cells, even though PAX3 was effectively
knocked down in these cells. Although two biological replicates were included, the lack of
knockdown of MITF and other differentiation genes in adult melanocytes after silencing of
PAX3 was not surprising considering the lack of effective PAX3 inhibition in these cells and
additional experiments are required to confirm this.
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Figure 25: Remaining expression levels (%) of PAX3 downstream targets MITF, DCT, HES1, SOX9 and NES in adult (NHEM (I)) and
neonatal (NHEMn) melanocytes and primary melanoma (WM115) and metastatic melanoma (M14) cell lines following PAX3
knockdown with siRNA (siPAX3). Target gene expression levels were calculated as the fold change over the negative control (siNC)
and converted to a percentage. Asterisk (*) indicates significant difference, p≤0.05. siPAX3 –D1, 2, 3 = Day 1, 2, 3 of PAX3 silencing
experiments; si NC D1, 2, 3 = Day 1, 2, 3 of negative control silencing experiment run in parallel with PAX3 silencing. Each silencing
experiment was performed in duplicate using a biological replicate.
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7.4.2 Expression levels of PAX3 downstream targets involved in
cell proliferation following PAX3 silencing
The results in Figure 26 show the percentage of remaining expression of CCNA2 and TPD52,
genes involved in cell proliferation, after transfection of cells with PAX3 siRNA. The results
indicate that CCNA2 is significantly downregulated in adult melanocytes following PAX3
knockdown (p<0.05). By contrast, primary and metastatic melanoma cells express
significantly less TPD52 after PAX3 knockdown (p=0.021, p=0.004, respectively). These
findings suggest that key cell proliferation genes are differently regulated by PAX3 in adult
melanocytes and primary and metastatic melanoma cells.
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Figure 26: Expression levels (%) of PAX3 downstream targets CCNA2 and TPD52 in adult (NHEM (I)) and neonatal (NHEMn)
melanocytes and primary melanoma (WM115) and metastatic melanoma (M14) cell lines following PAX3 knockdown with
siRNA (siPAX3). Target gene expression levels were calculated as the fold change over the negative control (siNC) and
converted to a percentage. Asterisk (*) indicates significant difference, p≤0.05. siPAX3 –D1, 2, 3 = Day 1, 2, 3 of PAX3 silencing
experiments; si NC D1, 2, 3 = Day 1, 2, 3 of negative control silencing experiment run in parallel with PAX3 silencing. Each
silencing experiment was performed in duplicate using a biological replicate.
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7.4.3 Expression levels of PAX3 downstream targets involved in
cell survival following PAX3 silencing
When analysed after transfection of cells with PAX3 siRNA, the metastatic melanoma cell
line showed significant downregulation of BCL2L1 expression (p<0.05) on the second day
post-transfection (Figure 27). Interestingly, BCL2L1 expression was significantly higher on
days 1 and 3 post-transfection (p<0.05). The primary melanoma cell line exhibited a
significant decrease in PTEN mRNA expression post PAX3 silencing (p=0.046) (Figure 27).
Thus, PAX3 potentially differentially regulates genes responsible for cell survival in primary
and metastatic melanoma cells compared to melanocytes.
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Figure 27: Expression levels (%) of PAX3 downstream targets BCL2L1, PTEN and TGFβ1 in adult (NHEM (I)) and neonatal
(NHEMn) melanocytes and primary melanoma (WM115) and metastatic melanoma (M14) cell lines following PAX3
knockdown with siRNA (siPAX3). Target gene expression levels were calculated as the fold change over the negative control
(siNC) and converted to a percentage. Asterisk (*) indicates significant difference, p ≤ 0.05. siPAX3 –D1, 2, 3 = Day 1, 2, 3 of
PAX3 silencing experiments; si NC D1, 2, 3 = Day 1, 2, 3 of negative control silencing experiment run in parallel with PAX3
silencing. Each silencing experiment was performed in duplicate using a biological replicate.
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7.4.4 Expression levels of PAX3 downstream targets involved in
cell migration following PAX3 silencing
The CXCR4 gene was the only cell migration gene that was shown to be downregulated
following PAX3 silencing, particularly in neonatal melanocytes (p= 0.016) and in the primary
melanoma cell line (p= 0.013) (Figure 28).
In summary, PAX3 knockdown caused a dramatic and significant decrease in genes
associated with differentiation in primary melanoma cells, but less so in metastatic
melanoma cells.

Moreover, different proliferation genes were associated with PAX3

knockdown in melanocytes relative to melanoma cells, confirming previous work indicating
differential regulation of these pathways in melanocytes relative to melanoma cells.
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Figure 28: Expression levels (%) of PAX3 downstream targets MCAM, CSPG4 and CXCR4 in adult (NHEM (I)) and neonatal
(NHEMn) melanocytes and primary melanoma (WM115) and metastatic melanoma (M14) cell lines following PAX3
knockdown with siRNA (siPAX3). Target gene expression levels were calculated as the fold change over the negative control
(siNC) and converted to a percentage. Asterisk (*) indicates significant difference, p≤0.05. siPAX3 –D1, 2, 3 = Day 1, 2, 3 of
PAX3 silencing experiments; si NC D1, 2, 3 = Day 1, 2, 3 of negative control silencing experiment run in parallel with PAX3
silencing. Each silencing experiment was performed in duplicate using a biological replicate.
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8.

Discussion

The overall aim of this project was to confirm the regulation of selected downstream target
genes by PAX3 and to determine the mechanism of their differential regulation in
melanoma cells compared to melanocytes. It was hypothesised that differential regulation
results from different PAX3 alternate transcript expression or different post-translational
modifications of the protein in these cells.
We showed here that there are indeed differences in PAX3 expression in melanocytes and
melanoma cells. Firstly, we identified a discrepancy between PAX3 mRNA and protein levels
in adult melanocytes, indicating that ubiquitination or miRNA activity play a role in PAX3
regulation in these cells. Furthermore, we found that PAX3 transcript expression profiles
differ in melanoma cells compared to melanocytes. Our results also suggested that PAX3
protein isoforms undergo different post-translational modifications in metastatic melanoma
cells compared to melanocytes. Lastly we demonstrated that selected downstream target
genes are indeed regulated by PAX3, with some of these downstream targets being
differentially regulated in melanocytes compared to melanoma cells.
Given the significant role of PAX3 in melanocyte development, and the significant
expression of PAX3 in melanoma, the role of PAX3 in melanoma cells needs to be
comprehensively clarified. The outcomes of this study further our understanding of the role
of PAX3 in melanoma and ultimately, through further research, may lead to PAX3 becoming
a target for therapeutic treatment.

8.1

PAX3E expression is downregulated in melanoma cells compared to
melanocytes

One way in which downstream target genes of PAX3 could be differentially regulated is
through alternate transcript expression. Each of the PAX3 transcripts has been shown to
produce a protein with a different function. Our data from RNA sequencing revealed that
the PAX3E transcript is expressed at significantly lower levels in metastatic and primary
melanoma cells compared to adult melanocytes (Figure 19). The role of PAX3E is thought to
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be to reduce proliferation of melanocytes and to increase apoptosis (Wang et al., 2006). If
PAX3E is downregulated in primary and metastatic melanoma cells, this could result in an
increase in the proliferation of melanoma cells and a decrease in activation of apoptosis
pathways, resulting in melanoma progression. This needs to be further investigated using
additional cell lines and confirmed in melanoma tissue samples. Moreover, confirmation of
a decrease in PAX3E protein should be confirmed in melanoma tissue samples with PAX3E
specific antibodies.
Further research is also required to identify a mechanism whereby the action of this
individual PAX3 isoform may influence melanomagenesis, perhaps giving melanoma cells
the ability to proliferate, migrate, survive and maintain a “stem cell-like” state as in
melanoblasts.

8.2

Differential PAX3 acetylation, phosphorylation and ubiquitination
in metastatic melanoma cells compared to primary melanoma cells
and melanocytes

Another way that PAX3 could differentially regulate downstream target genes is through
post-translational modifications. Previous research has demonstrated acetylation,
phosphorylation and ubiquitination of PAX3 in neuroblasts and myoblasts, causing these
precursor cells to differentiate into their pre-determined adult forms (Boutet et al., 2010;
Boutet et al., 2007; Dietz et al., 2011; Ichi et al., 2011; Miller et al., 2008). Our results
suggest that PAX3 possibly undergoes acetylation, phosphorylation and ubiquitination in
adult melanocytes, neonatal melanocytes, primary melanoma cells and metastatic
melanoma cells, however, the isoforms that undergo these modifications differ between
metastatic melanoma cells relative to the other three cell types. Our results show that the
acetylated, phosphorylated and ubiquitinated PAX3 product in the metastatic melanoma
cell line could be one, or a combination, of PAX3C, PAX3D and/or PAX3E isoforms. By
contrast, the primary melanoma cell line and adult and neonatal melanocytes have isoforms
PAX3G and/or PAX3H, with post-translational modifications.
Thus it is possible, from our results, that different PAX3 isoforms are postranslationally
modified in metastatic melanoma cells compared to primary melanoma cells and
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melanocytes and this could be one important mechanism by which differential downstream
target gene regulation occurs in metastatic melanoma cells. Interestingly, neonatal
melanocytes seem to lack ubiquitination of all PAX3 isoforms, indicating that all isoforms are
possibly required at maximal levels during this time period. The presence of differential
protein modifications in the four cell types could explain the differential regulation of
downstream target genes in these cells, leading to differences in cellular function and
phenotype and may contribute to the differential regulation of pathways associated with
melanoma.
Different PAX3 isoforms possesses different amino acid residues and thus different sites at
which acetyl, phosphate and ubiquitin moieties can attach (Boutet et al., 2010; Boutet et al.,
2007; Dietz et al., 2011; Ichi et al., 2011; Miller et al., 2008). Although the sites for
acetylation, phosphorylation and ubiquitination have been identified in PAX3, not all PAX3
isoforms possess all of these sites.
Acetylation of the PAX3 protein has been demonstrated by Ichi, et al. (2011) to occur at
lysine residues 437 and 475 of the PAX3 protein. More recently, potential acetylation sites
have been discovered at lysine residues 107, 116, 182 and 183 (Figure 29)(Cell Signaling
Technology). Isoforms PAX3G and PAX3H contain only the more recently discovered
potential sites for acetylation, while isoforms PAX3C, PAX3D and PAX3E contain both sites
required for acetylation. Since acetylation of the isoforms will only increase their molecular
weight by a maximum of 252Da (if all six sites are acetylated), which is not separable by SDSPAGE, it is indeed possible that PAX3 isoforms C, D and/or E are differentially acetylated in
metastatic melanoma cells, affecting downstream target gene regulation.
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Figure 29: Additional potential sites of acetylation on the PAX3 protein (lysine (K) residues
107, 116, 182 and 183) (Cell Signaling Technology).

Previous research has demonstrated that acetylation of PAX3 causes it to repress, rather
than activate, the same promoter on downstream target genes (Ichi et al., 2011). Since
alternate PAX3 isoforms differentially regulate cellular function (Wang et al., 2006). , and
these isoforms are potentially variably acetylated, it is plausible that differential acetylation
of these isoforms differentially regulate cellular function, adding a layer of complexity in the
role of PAX3 regulation of downstream target genes.
Serine residues 201, 205 and 209 of the PAX3 protein are possible sites of phosphorylation
(Dietz et al., 2011; Miller et al., 2008). Isoform PAX3A does not contain serine residues at
positions 201, 205 and 209 and therefore evades phosphorylation at these sites. The
remaining PAX3 isoforms (PAX3B-PAX3I) do possess these identified sites for
phosphorylation.
Posttranslational phosphorylation of PAX3 is actioned by GSK-3β (glycogen synthase kinase
3 beta) and CK2 (formerly casein kinase II) (Dietz et al., 2011; Kubic et al., 2012). Inhibition
of GSK-3β results in a decrease in PAX3 expression in melanoma cells thereby altering
proliferation states and regulation of apoptosis and terminal differentiation (Kubic et al.,
2012). It is possible that the differential phosphorylation of PAX3 by GSK-3β could alter
these cellular processes through either degradation of the protein, similar to that which has
been shown with β-catenin (Aberle et al., 1997), or stabilisation and activation of the
protein and alteration of its function via activation or repression of downstream targets
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(Takeda et al., 2000a; Zeng et al., 2005). Again, the alternate PAX3 isoforms have the
potential to differentially regulate cellular functions and this could be achieved through the
variable phosphorylation of PAX3 isoforms, as we have demonstrated here, which could
lead to differential activation or repression of downstream target genes.

Here, we

identified that between each of the cell lines, several downstream target genes of PAX3
were differentially regulated. Furthermore, PAX3 was found to be differentially
phosphorylated in metastatic melanoma cells compared to primary melanoma cells and
adult and neonatal primary melanocyte cells cultures. Thus, it is possible that
phosphorylation of the PAX3 protein contributes to differential downstream target gene
regulation.
Ubiquitination of the PAX3 protein occurs at the same lysine residues as acetylation (K437
and K475) (Boutet et al., 2010; Boutet et al., 2007), meaning that, like acetylation,
ubiquitination of isoforms PAX3C, PAX3D and PAX3E can occur. Ubiquitination of the PAX3
protein enables it to be recognised by the proteosomal degradation pathway and, at the
required time during development, has been shown to cause cells to differentiate (Boutet et
al., 2010; Boutet et al., 2007). This indicates that PAX3 degradation would remove its
activation or repression of downstream target genes and the differential ubiquitination of
PAX3 isoforms could be a mechanism underpinning differential downstream target gene
regulation.
Ubiquitin moieties would increase the molecular weight of the protein by up to 52.8kDa if
all six possible lysine residues are ubiquitinated, a size difference separable by SDS page.
Since our suspected product has the same molecular weight as acetylated and
phosphorylated PAX3 in primary and metastatic melanoma cells and adult melanocytes, it is
possible that fewer sites on the PAX3 protein are ubiquitinated in these cell types.
Although PAX3 isoforms are shown to be ubiquitinated in metastatic melanoma, primary
melanoma and adult melanocytes, they appear not to be so in neonatal melanocytes. There
is however no significant difference in PAX3 protein levels between these four cell types, so
it is possible that the PAX3 isoforms ubiquitinated in these cell types are not the
predominant forms or all PAX3 isoforms are not ubiquitinated and this is evident from our
results.
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Real-time qPCR and western blot analyses on each of the cell lines and primary melanocytes
were performed to confirm PAX3 expression in all of these cell types. However, from these
results, it can be seen that there is a discrepancy between the levels of mRNA and protein in
adult melanocytes (Figures 16 and 18, respectively). RT-qPCR results show that PAX3 is
expressed at significantly higher levels in adult melanocytes, while PAX3 protein levels in
adult melanocytes do not differ significantly from those of primary or metastatic melanoma
cells. Although this was not an expected finding from our research, it supports our
hypothesis that there is differential regulation of PAX3 in melanocytes relative to melanoma
cells and this is possibly by ubiquitination. Furthermore, our results indicate that PAX3
ubiquitination is not present in neonatal melanocytes. By contrast it is present in primary
and metastatic melanoma and adult melanocytes, however different isoforms are
ubiquitinated. Ubiquitination of PAX3 in adult melanocytes may therefore contribute to the
lower PAX3 protein levels in these cells.
PAX3 is ubiquitinated differently in melanoma and melanocyte cells, meaning it is possible
that the PAX3E isoform is differentially lost in these cells, influencing downstream pathway
regulation. However, although the PAX3E mRNA transcript is downregulated in melanoma
cells, this is not evident in overall PAX3 protein levels, since there is no significant difference
in protein levels between cell types. A difference in levels of this protein may not be evident
on its own, or the difference in mRNA levels may not translate to differences in protein
levels and further research is required to demonstrate differences in PAX3E protein levels in
the different cell types, where differences may be due to ubiquitination.
Changes in mRNA and protein expression are generally attributable to ubiquitination or
regulation by miRNA. To date, the miRNAs shown to regulate Pax3 expression in the
myogenic lineage are miR-1, miR-27b and miR-206, particularly in embryonal and alveolar
rhabdomyosarcoma (Li et al., 2012) and could possibly regulate PAX3 expression in
melanoma. In addition miR-211 has been associated with melanoma, and is shown to
repress an upstream regulator of PAX3, BRN2 (Boyle et al., 2011). miR-211 is reduced in
melanoma cell lines in comparison to melanocytes and overexpression of miR-211 in
melanoma cell lines inhibits cell invasion (Boyle et al., 2011). In this way, it is possible that
other miRNAs exist that have the potential to regulate PAX3.
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8.3

Knockdown of PAX3 differentially downregulates key genes
involved in cell differentiation, proliferation, migration and survival
in melanoma cells compared to melanocytes

Previous research conducted by our group identified 13 potential downstream target genes
of PAX3, several of which were differentially regulated in melanoma cells compared to
melanocytes (Medic et al., 2011). In order to further clarify the role of PAX3 in melanoma,
regulation of these genes in different cell types of melanocytic lineage were assessed
following PAX3 silencing and then downstream target gene expression was analysed.
Ultimately, the aim was to confirm the regulation of these genes by PAX3 in normal
melanocytes, through primary melanoma cells, to metastatic melanoma cells and to
determine whether PAX3 plays a role in cell migration, proliferation, survival and
differentiation in all of these cell types through regulation of specific target genes.
MITF is a key gene involved in melanocyte differentiation, survival and proliferation
(Watanabe et al., 1998). Our results indicate that MITF expression following PAX3 silencing
is decreased significantly in primary neonatal melanocytes and melanoma cells and,
although not significant, trends toward lower expression in adult melanocytes. This suggests
that PAX3 regulates MITF in melanocytes and melanoma cells. Furthermore, the regulation
of MITF by PAX3 in neonatal melanocytes and primary and metastatic melanoma cells
indicates that PAX3 maintains tight control of differentiation pathways in these cells to
regulate proliferation, migration and maintenance of an undifferentiated phenotype, which,
in melanoma cells, may contribute to melanoma progression (Cronin et al., 2009). The
knockdown of HES1, a marker of undifferentiated cells which aids in survival of melanocyte
precursors (Moriyama, 2006), observed here in neonatal melanocytes, confirms the role of
PAX3 in maintenance of undifferentiated cell phenotype through this gene in melanocytes
but not melanoma cells.
By contrast, our results showed that in adult melanocytes, PAX3 silencing did not cause a
significant downregulation of any of the tested genes involved in cell differentiation (MITF,
DCT, HES1, SOX9, NES). This is presumably due to the fact that the silencing was not efficient
or possibly that differentiation genes are not as effectively regulated by PAX3 in these
already differentiated cells.
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Following PAX3 silencing, only primary melanoma cells exhibited DCT downregulation. In
normal melanoblasts, the inhibition of DCT by PAX3 causes these cells to remain in their
undifferentiated state, allowing them to maintain their proliferation, migration and survival
properties (Lang et al., 2005), so in primary melanoma cells, this regulation of DCT by PAX3
could similarly maintain a relatively undifferentiated state.
As shown previously by Wang et al. (2007), we observed regulation of CCNA2 by PAX3 in
normal melanocytes. Notably, cell cycle regulators CCNA2 and TPD52 were differentially
regulated in adult melanocytes and melanoma cells following PAX3 silencing. We showed
here that PAX3 regulates CCNA2 in adult melanocytes, whereas TPD52 is regulated by PAX3
in melanoma cells. This confirms earlier findings by Medic et al. (2011), who also showed
differential regulation of TPD52 in melanocytes and melanoma cells. The regulation of
TPD52 by PAX3 in melanoma cells could be one mechanism underpinning an alternative
PAX3-driven mechanism of cell survival of melanoma cells relative to melanocytes and
requires further investigation.
Here we also demonstrated that PAX3 regulates two key cell survival genes in melanoma,
while these do not appear to be controlled by PAX3 in melanocytes. BCL2L1 and PTEN are
both downregulated in response to PAX3 silencing in melanoma cells. In particular, since
BCL2L1 inhibits apoptosis, its regulation by PAX3 in metastatic melanoma cells may be a cell
survival mechanism (Margue et al., 2000). PTEN is knocked down in response to PAX3
silencing in primary melanoma cells, indicating that PTEN is regulated by PAX3. However
regulation may be in an indirect manner, activating a separate pathway involved in PTEN
regulation, as previously PAX3 has been shown to inhibit PTEN expression in melanoma cells
(Li et al., 2007). Furthermore, PTEN has previously been shown to be differentially regulated
in melanoma cells compared to melanocytes (Medic et al., 2011).
The variable results demonstrated in differential downstream target gene regulation limit
the efficacy of this experiment. The presence of very few significantly downregulated
downstream target genes in neonatal and adult melanocytes may be attributable to the
insufficient knockdown of PAX3. Although the silencing procedure was tested for efficiency
using siGAPDH as a positive control, and GAPDH was found to be sufficiently knocked down
in adult and neonatal melanocytes, it is possible that PAX3 silencing was not as effective in
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these cells due to their slow turnover rate. Alternately, other potential downstream target
genes are differentially regulated by PAX3 in melanocytes, thus further investigation is
needed, in more samples and possibly in tissues, in order to gain an improved
representation of the role of PAX3 in regulating these downstream target genes.
In summary, in this project, we have demonstrated PAX3 regulation of downstream target
genes that drive key pathways in cell differentiation, proliferation, migration and survival.
Furthermore, we have shown that this regulation differs in melanocytes relative to
melanoma cells and that this differential regulation could be attributable to alternate
transcript expression, shown through the downregulation of PAX3E in melanoma, or
differential protein modifications of the PAX3 isoforms.

8.4

Limitations of the study and suggested future experiments

The most significant limitation of this study is that all experiments were performed in one
cell line per cell phenotype limiting the general applicability of these findings. Additional
experiments in additional cell lines for each phenotype in vitro and in tissue are required to
further identify the role of PAX3 in differential activation of downstream target genes. There
is however only one commercially available neonatal cell line and very few adult melanocyte
primary cell cultures, limiting what is possible in vitro. Alternately, additional experiments
could be conducted using tissue explants or fresh tissue samples to gain a more
comprehensive understanding of the complex role of PAX3 in skin homeostasis and in
melanomagenesis.
Different antibodies against PAX3 preferentially recognise and bind to different PAX3
isoforms. When used for immunoprecipitation and western blotting, this contributed
significantly to difficulties with experiment optimisation. New transcript-specific antibodies
have recently become available commercially however these have not been confirmed in
the literature, as useful for immunoprecipitation. Furthermore, optimisation of these
experiments with additional cell lines, and alternative immunoprecipitation kits with a range
of PAX3 antibodies, is required to further our understanding of these isoforms.
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The lack of change in downstream target gene regulation indicated by our results suggests
that either these genes do not depend on PAX3 for their regulation, or more likely,
insufficient PAX3 silencing prevented us from observing any effect on the target. This means
that further silencing experiments in these cell types is required to determine whether PAX3
was sufficiently knocked down and whether the results acquired are a true representation
of these cell types. The limited number of biological replicates reduces confidence in the
PAX3 silencing data and therefore an increase in the number of biological replicates is
required for each cell line. In order to increase the efficiency of PAX3 knockdown in
melanocytes, the transfection procedure should take place over 48 hours, rather than the
24 hour time lapse used here. It is possible that the inefficient knockdown of PAX3 is due to
the slow turnover of melanocytes compared to melanoma cells. Improving the efficiency of
this experiment will enable us to determine which downstream target genes are
differentially regulated in melanocytes compared to melanoma cells and will help to
broaden our understanding of the mechanisms underpinning differential downstream target
gene regulation in melanoma cells compared to melanocytes.
Additionally, immunoprecipitation of the individual PAX3 isoforms, using specific antibodies,
followed by assessment of the isoforms for differential post-translational modifications in
melanoma cells compared to melanocytes will further our understanding of the individual
roles of the PAX3 isoforms in melanoma compared to normal skin melanocytes.
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9.

Conclusion

In conclusion, melanoma is an extremely aggressive skin cancer and is highly drug resistant
(Chen et al., 2006; Chin et al., 2006), emphasising the need to define mechanisms involved
in the development and progression of this cancer so as to make advances in the
therapeutic treatment of melanoma. Previous research has demonstrated that potential
downstream target genes of PAX3 are differentially regulated in metastatic melanoma
compared to normal human epidermal melanocytes (Medic et al., 2011). We hypothesised
that this differential regulation of downstream targets by PAX3 could be attributable to
alternate PAX3 transcript expression or differences in post-translational modifications of the
PAX3 protein between metastatic melanoma cells and normal adult human melanocytes.
Thus, we assessed the PAX3 transcript expression, PAX3 post-translational modification
profiles and the regulation of downstream target genes in normal human adult and
neonatal melanocytes relative to primary and metastatic melanoma,
Here we have identified that the PAX3E transcript is downregulated in metastatic and
primary melanoma cells compared to normal adult human melanocytes. Since the role of
PAX3E in normal melanocytes is to reduce proliferation and increase apoptosis (Wang et al.,
2006), our results suggest that its downregulation in melanoma could be one of the
mechanisms underpinning the ability of melanoma cells to evade apoptosis and increase cell
proliferation. Furthermore, we have shown that PAX3 is regulated at a post-translational
level in normal adult and neonatal melanocytes and in primary and metastatic melanoma
cells, with differential modifications of PAX3 isoforms in metastatic melanoma cells
compared to normal melanocytes and primary melanoma cells. Moreover, we showed that
PAX3 in normal neonatal human melanocytes is not ubiquitinated, in contrast to the other
three cell types, confirming differential regulation of PAX3 at different developmental
stages. Finally, we have confirmed differential regulation of downstream target genes
involved in differentiation, proliferation, migration and cell survival between normal human
adult and neonatal melanocytes, and primary and metastatic melanoma cells.
The major limitation of this study was the apparent preferential binding of the PAX3
antibodies to different isoforms, making it difficult to immunoprecipitate the PAX3 protein
and effectively visualise it using western blotting. Thus, future experiments should look into
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using isoform specific antibodies that have recently become commercially available.
Furthermore, silencing experiments need to be repeated and expanded to include more
samples, in order to confirm differential regulation of downstream targets between
melanocytes and primary and metastatic melanoma cells. Finally, transcript expression
profiling should be performed on an increased number of samples.
By further analysis, the mechanisms by which PAX3 differentially regulates downstream
target genes could become clearer, furthering our knowledge of the potential role of PAX3
in melanoma progression. Given the importance of PAX3 in the development of
melanocytes and its expression in the majority of melanoma cells, knowledge of differences
in PAX3 regulated mechanisms between normal cells and melanoma cells that lead to
melanoma progression could provide tools for therapeutic manipulation of melanoma cells
while sparing the normal cells.
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